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Abstract
The success of the USA300 strain of methicillin resistant Staphylococcus aureus can be attributed
in part to its enhanced ability to overcome innate defenses of the skin including sebum, which
provides a source of antimicrobial unsaturated free fatty acids (uFFA). We have previously
identified farE and farR genes that confer S. aureus resistance to uFFA, respectively encoding a
uFFA efflux pump and a TetR family regulator required for farE expression. However, the exact
regulatory mechanism of FarR remains to be elucidated. Here, we show the importance of a
conserved TAGWTTA motif in FarR operator sites, such that the loss of this motif in
autoregulatory operator sites caused a de-repression of FarR. However, this de-repression did not
cause an increase in resistance to uFFA. Additionally, we have identified the importance of
cysteine residues for FarR function. These findings shed further light on the mechanisms of S.
aureus resistance to antimicrobial uFFA.

Keywords: Antimicrobial fatty acids, RND family efflux pump, TetR family regulator,
Staphylococcus aureus, farR, farE
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Summary for Lay Audience

Staphylococcus aureus colonizes approximately 30% of the population asymptomatically and yet
can cause mild to severe infections. Frequently, these infections are caused by the colonizing
strain. Therefore, understanding the mechanism by which S. aureus persists on, and colonizes the
skin is of importance. USA300 is the predominant strain of community acquired methicillin
resistant S. aureus in North America and is the leading cause of skin and soft tissue infections. The
success of USA300 can be attributed in part to their enhanced ability to overcome the immune
defences of the skin, which include fatty acids that are found in the sebum. These fatty acids are
toxic and therefore, USA300 employs several strategies to overcome this toxicity. One way is
through the removal of fatty acids from the bacterial cell through the protein FarE. Here, we further
study the regulation of FarE by its regulator, FarR. Overall, these findings shed further light into
fatty acid resistance strategies employed by S. aureus.
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1 Introduction
1.1 Overview of Staphylococcus aureus
1.1.1 Background
Staphylococcus aureus is a Gram-positive, spherical bacterium belonging to the Firmicutes
phylum. The etymology of S. aureus describes the morphology of this species very well. The prefix
derives from the ancient Greek “staphylē” for bunch of grapes, and describes the characteristic
clusters it forms, while the species name derives from the Latin “aurum”, describing its golden hue
when grown on solid media. S. aureus exhibits duality in its nature as it colonizes approximately
30% of the population asymptomatically yet is able to cause mild to severe infections
opportunistically. As such, it is classified as a pathobiont (1).

The preferred site of S. aureus colonization is the anterior nares, but it is also known to colonize
the skin and other mucosal surfaces such as the throat, vagina, perineum, and axillae (2, 3). Nasal
carriage of S. aureus is characterized by three distinct carriage groups, persistent carriers (20%),
intermittent carriers (60%) and non-carriers (20%) (4, 5). The reported 30% of the general
population that is colonized by S. aureus is composed of a mix of persistent and intermittent
carriers (4). Persistent carriers differ from intermittent carriers in several ways. Persistent carriers
usually only harbor one distinct strain of S. aureus over time, while intermittent carriers may carry
different strains over time. Additionally, S. aureus is isolated in greater abundance from persistent
carriers compared to intermittent carriers (6). Moreover, S. aureus can more often be isolated from
different sites of the body in persistent carriers, other than the anterior nares (3). Therefore,
colonization status is a determinant of the development of S. aureus infection, as persistent carriers
are at a greater risk of developing an infection due to the increased pathogen burden (7). It has
been shown that S. aureus infections often appear to be of endogenous origin (8). However, the
mortality rate of S. aureus caused bacteremia has been shown to be greater in non-carriers than
those who are colonized (9). Infections caused by S. aureus usually manifest as soft tissue
infections and abscesses. However, it can also cause severe, and life-threatening complications
such as endocarditis and osteoarticular infections.
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1.1.2 Pathogenesis
S. aureus is able to infect virtually every tissue of the body due to the large variety of virulence
factors at its disposal. Once the integrity of the epithelial barrier is compromised either through
skin or hair follicle abrasions, surgery or indwelling medical devices, S. aureus is able to initiate
infection by adhering to host factors using microbial surface components recognizing adhesive
matrix molecules (MSCRAMMs). S. aureus encodes up to 20 MSCRAMMs that bind to host
factors such as collagen, fibrinogen, and fibronectin (10). In order to survive within the host, S.
aureus must additionally overcome nutritional immunity, by which the host sequesters vital
nutrients to limit the proliferation of the invading pathogen. One example of nutritional immunity
is the sequestration of iron. The majority of iron within mammals is located intracellularly, and
the remainder is bound by high-affinity iron-binding proteins (11). One mechanism S. aureus uses
to acquire iron is the secretion of siderophores, which have an extremely high affinity for iron,
such that they are able to strip iron from host iron-binding proteins (12).

Initial infection of skin and soft tissue usually manifests as abscesses, from which the bacteria can
disseminate to infect other tissues of the body. Although the formation of abscesses beings with
localized recruitment of immune cells, S. aureus has many immune evasion mechanisms to thwart
both the innate and adaptive immune system. To evade phagocytosis, S. aureus secretes
chemotaxis inhibiting proteins and formyl peptide receptor-like 1 inhibitory protein, which both
interfere with the chemotactic ability of neutrophils (13, 14). Moreover, staphylococcal protein
A, a surface protein binds the Fc of immunoglobins, capturing the immunoglobin in the incorrect
orientation needed to initiate phagocytosis through opsonization (15). In the event that
phagocytosis does occur, S. aureus is able to evade killing by reactive oxygen species (ROS) via
proteins such as catalase and superoxide dismutase (16). Furthermore, staphyloxanthin, the
pigment that gives rise to the characteristic golden colour of S. aureus, has anti-oxidant properties,
further contributing to protection against ROS (17). Finally, S. aureus secretes pore-forming
toxins, such as Panton-Valentine Leukocidin (PVL), and -toxin to kill neutrophils (18,19).
Therefore, due to the large amount of immune cell lysis by S. aureus, the centre of abscesses
contains an exudate of necrotic immune cells (20).
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To disseminate from abscesses, global regulators such as agr can sense the population density of
S. aureus. When the density is high, surface receptors for adhesion are downregulated while
secreted effectors are upregulated. This allows S. aureus to leave the initial site of colonization
and spread to other body tissues (21). An important secreted protein is -toxin. As mentioned
previously, -toxin lyses neutrophils but also contributes to the dermonecrosis of abscesses
through the lysis of erythrocytes, epithelial cells, and endothelial cells (22). Additionally, -toxin
activates a disintegrin and metalloprotease-10 (ADAM10), leading to subsequent proteolysis of Ecadherin. This results in the collapse of adherens junctions that connect epithelial cells to one
another, allowing S. aureus to disseminate (22). S. aureus also secretes many additional tissuedegrading enzymes, including extracellular proteases. The staphylococcal proteolytic cascade is
composed of the proteases aureolysin, SspA, and SspB and these proteases have been shown to
degrade immunoglobin, complement, and elastin, an important protein of the extracellular matrix
(23, 24). This pathway has also been found to be induced by unsaturated free fatty acids, which
are present on the skin and within abscesses (25). Additional virulence factors of S. aureus include
the superantigen toxic shock syndrome toxin-1, (26). These molecules force non-specific
activation of T-cells, leading to a massive release of cytokines. This cytokine storm can cause toxic
shock syndrome. Finally, S. aureus is able to form biofilms in which they are protected from
immune cells and antibiotics. Biofilms are often formed on indwelling medical devices, causing
chronic infections in these patients (27).

1.1.3 Emergence of antibiotic resistance
Before the advent of penicillin, bacteremia caused by S. aureus had a mortality rate of between
75-83% (28). Therefore, the discovery of penicillin in 1928 by Sir Alexander Fleming was
revolutionary for modern medicine, and for this discovery, he was awarded a Nobel prize.
Penicillin functions by binding transpeptidases/penicillin-binding proteins (PBPs) that are
responsible for crosslinking the peptidoglycan of the cell wall. However, in 1942, a few years after
the clinical introduction of penicillin, resistant strains of S. aureus began to emerge (29). These
strains produced penicillinase, a -lactamase which hydrolyses the active -lactam ring of
penicillin, rendering it ineffective. Methicillin, a penicillinase-resistant -lactam antibiotic was
later introduced, but once again, methicillin-resistant strains arose soon after its introduction.
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Horizontal gene transfer with Staphylococcus epidermidis, a commensal skin bacterium, lead to
the acquisition of the SCCmec cassette, which contains the gene mecA. mecA encodes for PBP2, a
PBP with lower affinity for -lactams (30). The acquisition of mecA not only renders MRSA
resistant to methicillin but all other -lactam derived antibiotics: penicillins, cephalosporins, and
carbapenems. Until the 1990s, these strains of MRSA were largely confined to the hospital setting
(HA-MRSA), causing nosocomial infections. HA-MRSA strains usually harbor SCCmec types I,
II, and III, which also carry resistance genes for multiple antibiotics such as kanamycin, neomycin,
tetracycline, and erythromycin (29).

However, in the early 90s, these MRSA strains were found in the community in healthy patients
who had not had prior exposure to a healthcare setting and were termed community-acquired
MRSA (CA-MRSA). CA-MRSA usually harbor SCCmec type IV, V, and VI. In contrast to the
SCCmec types harboured by HA-MRSA, types IV, V and VI, do not carry multi-drug resistance,
and only carry resistance to -lactam derivatives (31). However, types IV, V, and VI are much
smaller in size than types I, II, and III, giving a fitness advantage in the absence of antibiotics (32).
Since the 90s, CA-MRSA of multiple lineages has been found on every continent. USA300 is the
predominant CA-MRSA strain found in North America and is the primary cause of skin and soft
tissue infections in the United States (33). Although initially only resistant to -lactam antibiotics,
resistance to other antibiotics such as macrolides and fluoroquinolones have also developed.
Additionally, reduced susceptibility to vancomycin and daptomycin in USA300 isolates has also
been found (34).

1.2 USA300 virulence
1.2.1 Origins and spread of USA300
Before the introduction of multilocus sequence typing (MLST) and staphylococcal protein A (spa)
typing, pulse-field gel electrophoresis (PFGE) was used to identify isolates of S. aureus. USA300
was first identified through this method, along with 8 other initial MRSA strains (USA100-800)
isolated from the United States (35). USA300 emerged from S. aureus MLST 8, which is the
presumptive ancestor of MRSA and the first to acquire the SCCmec cassette. Furthermore,
4

USA300 is speculated to have arisen from USA500, a strain of HA-MRSA, and differs from its
ancestor by several unique genomic features that render it particularly more aggressive and hypervirulent than other strains of CA-MRSA. USA300 harbors SCCmec type IV (36), and other
accessory genetic elements found in the USA300 genome include PVL, enterotoxins sek2 and
seq2, and the arginine catabolic mobile element (ACME), the latter being unique to USA300 (37).
PVL is a bacteriophage-encoded -pore toxin that lyses neutrophils, monocytes, and macrophages,
causing subsequent tissue necrosis through the release of inflammatory cytokines (31).

USA300 was first found only in North America, while other continents had their own predominant
strain of MRSA. The first known cases caused by USA300 were found in football players in
Pennsylvania and later was found to be responsible for an outbreak of soft tissue infections in
prison inmates in Mississippi (37). It was later found in other states in patients who had no prior
exposure to a healthcare setting. USA300 is now found across the globe in 36 countries across 5
continents, including North America, Colombia, Australia, Japan, Israel, which can be explained
in part due to increased international travel (38). In Canada, USA300 has been the predominant
strain of CA-MRSA since 2004 (39, 40).

1.2.2 Evasion of skin innate immune defenses
The human skin is an interface between the host and the environment, and therefore, the first line
of defence against invading pathogens. Not surprisingly, the skin has many immune defence
mechanisms to limit colonization and infection. Firstly, the tightly linked corneocytes of the
stratum corneum represent a physical barrier to invading pathogens (41). Skin also has a low
moisture content and is at a lower temperature than the rest of the body, which slows the replication
of pathogens (42). Chemical barriers are also secreted from the skin, including lysozyme,
antimicrobial peptides, and sebum. Antimicrobial peptides are small, charged peptides secreted by
keratinocytes that insert themselves into bacterial membranes, creating pores and disrupting
membrane integrity. Keratinocytes upregulate antimicrobial peptide production in response to the
wounding of the epithelial barrier or during infection (42).
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Human skin is coated by a lipid mixture, secreted by the sebaceous glands in the dermis of the
skin. It is composed of squalene, wax monoesters, cholesterol, cholesterol esters, and triglycerides.
The triglycerides are hydrolyzed by lipases secreted by the flora of the skin, and by an acid lipase
released by the lamellar granules of keratinocytes, releasing free fatty acids, giving the skin an
acidic pH (43). Sapienic acid (C16:1) and oleic acid (C18:1) are the main uFFAs to originate from
sebum, while linoleic acid (C18:2) and arachidonic acid (C20:4) are found in nasal secretions (44).
S. aureus is also exposed to linoleic acid during the context of infection, mainly in abscesses (45).
To exert their toxic effects on bacteria, free fatty acids are thought to enter the cell through passive
diffusion and cause subsequent disruption of membrane integrity, leading to an influx of H+ ions
and leakage of metabolites, affecting oxidative phosphorylation (46). Additionally, those with
deficiencies in uFFA production are more susceptible to skin infections caused by S. aureus (47).
Arachidonic acid also has a role in the oxidative burst produced by macrophages and neutrophils.
In this inflammatory burst, arachidonic acid is autoxidized by ROS to various electrophilic
molecules, including free aldehydes, ,-unsaturated carbonyls and isolevuglandins (48). These
reactive electrophiles damage the cellular machinery of S. aureus, leading to cell death.

The success of USA300 can be attributed, in part, in its ability to overcome these innate immune
defenses. Part of this is attributed to the acquisition of the arginine catabolic mobile element
(ACME) through horizontal gene transfer with Staphylococcus epidermidis, a commensal skin
bacterium (49). Arginine is an important mediator in the cutaneous immune response as it is
responsible for both initial inflammation and eventual resolution. Additionally, during the onset of
inflammation, arginine is metabolized to produce NO•. During the resolution of inflammation,
arginine is converted to ornithine, which is subsequently converted to polyamines. Polyamines are
necessary to promote proper tissue repair during wound healing. They are also toxic to S. aureus
at physiological concentrations. ACME contains the arc operon, which encodes the arginine
deiminase pathway genes. These genes catalyze the conversion of arginine to ornithine, as well as
ATP and ammonia, which is important as to deacidify the skin. However, ornithine is produced in
this reaction and is subsequently converted to toxic polyamines. To mitigate this issue, ACME
also encodes speG, a polyamine acetyltransferase that confers polyamine resistance to USA300
(50).
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1.2.3 Resistance to antimicrobial fatty acids
S. aureus employs three main mechanisms in which to protect against antimicrobial fatty acids;
modification of cell wall molecules and phospholipid bilayer, efflux pumps, and metabolic
detoxification. Upon exposure to antimicrobial fatty acids, S. aureus upregulates genes for
carotenoid biosynthesis. Carotenoids are lipophilic and can be inserted into the phospholipid
bilayer where, they increase the stability of the membrane (51). Staphyloxanthin, the carotenoid
which gives S. aureus its golden hue, is involved in this process as studies have shown a positive
correlation between pigment and resistance to oleic acid (52). IsdA is a surface protein and
adhesion factor that binds to fibrinogen, fibronectin and transferrin, and is required for nasal
colonization. However, IsdA has also been shown to mediate resistance to antimicrobial fatty
acids. The C-terminal tail of IsdA is anchored to the cell membrane. When IsdA expression is
upregulated, the hydrophobicity of the membrane decreases, thereby rendering the membrane less
susceptible to bactericidal fatty acids (53). Moreover, wall teichoic acid also confers resistance to
antimicrobial fatty acids. Wall teichoic acids are necessary for nasal colonization and are believed
to confer a high charge to the cell wall, thereby repelling antimicrobial fatty acids (54). S. aureus
also encodes efflux pumps in which to remove antimicrobial fatty acids once present in the
cytoplasm. Tet38, a tetracycline efflux pump, also removes palmitoleic acid from the bacterial cell
(55). Additionally, our lab has previously discovered farE, a RND-family efflux pump that
promotes efflux of arachidonic acid and linoleic acid (56). Finally, S. aureus is also able to
metabolically detoxify antimicrobial fatty acids. Fatty acid modifying enzyme (FAME) detoxifies
bactericidal fatty acids found in abscesses through their esterification to various alcohols (57).
Moreover, host-derived fatty acids can also be incorporated into phospholipid by fatty acid kinase
FakA and FakB1/2 (58).
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1.3 Fatty acid machinery of Staphylococcus aureus
1.3.1 Phospholipid composition and synthesis
The phospholipid bilayer of S. aureus is mainly comprised of three types of polar lipids,
phosphatidylglycerol, lysyl-phosphatidylglycerol, and cardiolipin (59). To maintain homeostasis
of the membrane, many organisms adjust the ratio of saturated to unsaturated fatty acids, making
the membrane more rigid and fluid, respectively. However, unlike many other bacteria such as
Bacillus subtilis, S. aureus does not encode desaturase enzymes, meaning that it is unable to
produce unsaturated fatty acids (60). Therefore, to regulate the fluidity of its membrane, S. aureus
also synthesizes both straight-chain and branched-chain fatty acids. Branched-chain fatty acids
(BCFA) are synthesized from the branched-chain amino acids (BCAA) leucine, valine, and
isoleucine, the latter of which gives the most membrane fluidity (61). As much as 55% of
phospholipids that make up the membrane in S. aureus are derived from BCFA (62). BCAA are
transaminated by the enzyme branched-chain amino acid transaminase (BAT), giving rise to
branched-chain -keto acids (62). These branched-chain -keto acids are then decarboxylated by
-keto acid dehydrogenase producing branched-chain acyl coenzyme A derivatives. In a series of
reactions performed by the fatty acid biosynthetic (Fab) proteins of the FASII cycle, the branchedchain acyl coenzyme A derivatives are elongated to produced long-chain acyl-acyl carrier protein
(ACP) (59). These long chain acyl-ACPs then feed into the remainder phospholipid synthesis,
which, in many Gram-positive bacteria, is carried out by the PlsXYC acyltransferase system. PlsX,
a peripheral membrane protein, catalyzes the transfer of the acyl group of long-chain acyl-ACP to
acyl-phosphate. PlsY then transfers the acyl group to glycerol-3-phosphate (G3P). Finally, PlsC
transfers a second fatty acid group to the acyl-G3P, creating phosphatidic acid (PtdOH), which is
the main intermediate of phospholipid synthesis in eubacteria. PtdOH can then be used to
synthesize phosphatidylglycerol, leading to the synthesis of lysyl-phosphatidylglycerol,
cardiolipin, and lipoteichoic acids. Deletion of plsY is lethal to S. aureus; however, when plsX is
deleted, the resulting strains are fatty acid auxotrophs (60, 64).
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1.3.2 Incorporation of exogenous fatty acid into phospholipids
It is unknown whether S. aureus is able to use host-derived fatty acid as an energy source through
-oxidation. However, S. aureus does possess another mechanism in which to utilize and de-toxify
exogenous fatty acids simultaneously. Additionally, the synthesis of both straight and branchedchain fatty acids is energetically expensive, and it would be optimal for S. aureus to make use of
the exogenous fatty acids found in the environment. Both saturated and unsaturated exogenous
fatty acids enter the cell through passive diffusion and by the pH gradient, are flipped to the inner
leaflet of the membrane. Once in the cell, saturated and unsaturated fatty acids are bound by the
fatty acid binding protein FakB1 and FakB2, respectively. Once bound by FakB1/2, they are
phosphorylated by the ATP-dependent fatty acid kinase FakA, creating an acyl-phosphate. The
resulting acyl-phosphate can either be converted to acyl-ACP to be extended through FASII
machinery or directly incorporated into phospholipid by the PlsXYC acyltransferase system,
producing phosphatidic acid, which can then be used to synthesize phosphatidylglycerol, lysylphosphatidylglycerol, cardiolipin and lipoteichoic acids (Fig 1.1). However, eventually the buildup
of uFFA surpasses the rate of membrane incorporation by FakA and the PlsXYC acyltransferase
system and will lead to cell death (46, 54).
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Figure 1.1 Incorporation of exogenous fatty acid into membrane phospholipids in S. aureus
Upon entry into the cell, exogenous fatty acids (FA) are bound by FakB and subsequently
phosphorylated by FakA. Phosphorylated fatty acids can either be extended by the FASII
machinery or can directly incorporated into membrane phospholipid. Figure adapted from Kuhn
et al. (59).

10

1.4 Resistance-nodulation division family transporters
Efflux pumps are commonly found in many bacterial species and represent important mediators
of antibiotic resistance. There are currently five defined classes of efflux pumps: the major
facilitator superfamily, the ATP-binding cassette superfamily, the small multidrug resistance
superfamily, the multidrug and toxic compound extrusion superfamily and the resistancenodulation division-superfamily (RND). RND family efflux pumps are able to transport a wide
range of substrates, including small hydrophobic compounds, metals, and antibiotics. The majority
of our knowledge of RND family efflux pumps comes from research done in Gram-negative
bacteria, and although RND family efflux pumps are present in Gram-positive species, they have
been less well characterized in these bacteria. A well-characterized RND family efflux pump is
the multidrug efflux AcrA-AcrB-TolC complex in E. coli, of which AcrB is an RND family efflux
pump that interacts with AcrA and TolC to form a tripartite complex. ArcB and TolC are
transmembrane proteins in the inner and outer membrane, respectively, and AcrA bridges the two
in the periplasm, creating a continuous channel to allow efflux of a substrate, which are typically
hydrophobic antibiotics or bile salts (55, 56). Although Gram-positive bacteria and
Mycobacterium species do not have an outer membrane, they still encode RND family efflux
pumps that bear homology to AcrB in E. coli, for example, MmpL in Mycobacterium tuberculosis
which transports lipids to the cell wall (67). S. aureus encodes three RND-family efflux pumps,
including FemT, which is thought to be involved in cell wall synthesis, SecDF, which plays a role
in protein secretion, and FarE which promotes efflux of uFFA (44, 56, 57).

1.5 TetR family transcriptional regulators
Bacteria use signal transduction systems to sense the environment around them to properly regulate
gene expression of antibiotic resistance genes and to maintain homeostasis of important
biochemical processes. Of these signal transduction systems, there are two main types; onecomponent and two-component signal transduction systems. One-component signal transduction
systems operate using one protein that is responsible for both the sensing of the environment and
gene regulation, whereas in the two-component system, the sensing and gene regulation is done
by different proteins (70).
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The TetR family of transcriptional regulators (TFR) is a group of one-component signal
transduction systems found in many species of bacteria. There are over 2500 known TFRs that are
responsible for a wide variety of functions, including antibiotic resistance, cell-cell signalling and
the metabolism of lipids, amino acids, and nitrogen. TFRs have an -helical structure, with helixturn-helix DNA binding domains that usually bind palindromic DNA sequences. The majority of
TFRs are known to be autoregulatory. Additionally, most of these regulators function to repress
their target gene, although some TFRs are known to be activators, as well as some functioning as
both repressor and activator (70–72). The DNA binding affinity of TFRs is also modulated after
binding a small molecule ligand, and in the case of a TFR regulating an efflux pump, the ligand is
usually the substrate of the efflux pump. All TFRs consist of an N-terminal DNA-binding domain
and a C-terminal domain that usually binds a ligand. The ligand-binding domain has the ability to
alter the DNA binding affinity of the N-terminal domain once bound to a ligand. TFRs usually
function as dimers; however, some members of this family may also function as tetramers or
through other oligomerization states. TFRs can also be further categorized into three subgroups
depending on the position and orientation of the gene encoding the regulator to that of the effector
protein. In type one TFRs, the TFR is divergently transcribed from the regulated target gene, and
this group makes up the majority of TFRs. The prototypic TFR, TetR is found in E. coli and is
responsible for regulating tetA, which encodes a tetracycline efflux pump, promoting resistance to
tetracycline. TetR is a type-1 TFR, and as such, it is divergently transcribed from tetA and functions
as a repressor of transcription. In the absence of its ligand, tetracycline, the TetR homodimer
remains bound to overlapping operator sequences in the intergenic segment, repressing the
transcription of both tetR and tetA. When tetracycline enters the cell, it is bound by TetR, causing
a conformational change in the protein in which it is unable to bind to the intergenic operator sites,
promoting the expression of both tetR and tetA (73).

However, there are many TFRs that, in part, deviate from the typical paradigms of TFR function.
An example of this is DhaS in Lactococcus lactis in which dihydroxyacetone metabolism is
regulated in a mechanism consisting of co-activator proteins. DhaQ binds the physiological ligand
dihydroxyacetone. The DhaQ-dihydroxyacetone complex then binds to DhaS, a member of the
TetR family. Only when DhaS binds the DhaQ-dihydroxyacetone complex is it able to activate the
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expression of genes required for dihydroxyacetone metabolism. DhaS is also an unconventional
TFR in the respect that it is a transcriptional activator and not a repressor (74).

TFRs can be found in S. aureus as well. QacA is a multi-drug efflux pump for quaternary
ammonium-type antiseptic compounds and is negatively regulated by the TFR QacR. QacR does
not bind to the promoter of qacA, which is unusual of TFRs. However, it does bind to an inverted
repeat located downstream of the qacA promoter. The binding of this inverted repeat may still
allow RNA polymerase to bind, but it would prevent the transcriptional machinery from being able
to fully access the gene. Both qacA and qacR are accessory genetic elements, encoded for on the
pSK616 plasmid (75–77). IcaR is a TFR in S. aureus that is chromosomally encoded. IcaR
regulates the icaADBC operon that is responsible for the biosynthesis of poly-N-acetlyglucosamine
for the formation of biofilms. IcaR represses the transcription of the icaABDC operon through the
binding of a TATTT motif. However, IcaR has not been shown not to be involved in autorepression
(68, 69). Finally, FarR another TFR in S. aureus regulated the RND family, unsaturated free fatty
acid efflux pump FarE. FarR is unusual in the sense that it both represses and activates farE (56).

1.6 FarE and FarR
1.6.1 Overview of FarE and FarR
S. aureus can detoxify and utilize uFFA by incorporating them into the phospholipid bilayer
through the FakA/B, and PlsXYC acyltransferase system. There are also other methods by which
S. aureus can increase their resistance to uFFA. For example, resistance to palmitoleic acid can be
conferred through several methods. Teichoic acids can restrict the access of palmitoleic acid to the
cytoplasmic membrane (54). S. aureus also encodes tet38, a major facilitator superfamily efflux
pump that promotes efflux of palmitoleic acid out of the cell (80). However, both of these methods
only promote resistance to palmitoleic acid. Our lab has found another mechanism by which S.
aureus can detoxify and increase their resistance to other uFFAs. We have previously identified
farE (SAUSA300_2489) and farR (SAUSA300_2490), a divergently transcribed regulator and
effector pair in USA300. farE encodes an 822 amino acid, 90.4kDa RND-family efflux pump that
promotes efflux of fatty acids, the expression of which can be induced by linoleic and arachidonic
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acid (56). farR encodes a 182 amino acid 21.9 kDa type-1 TFR with an N-terminal DNA binding
domain that is responsible for regulating farE. FarE and FarR are homologous to RND-family
efflux pump AcrB and its regulator AcrR a TFR, respectively. Genome annotations also assign
FarE to the MmpL family of proteins from Mycobacterium tuberculosis (81). FarE expression is
tightly regulated and is only expressed when induced by uFFA, with higher levels of induction
when exposed to arachidonic acid and linoleic acid, which are commonly found in the anterior
nares compared to sapienic acid which is found in sebum.

1.6.2 Features of the farER intergenic segment
As farR and farE are divergently transcribed, both of their promoters lie within the 144 nucleotide
long intergenic segment (Fig 1.2), and previous experiments in our lab have identified three
operator sites within: OfarE, OfarR, and OPAL1 (82). OfarE lies upstream of the farE promoter (PfarE)
and is situated in a position that would be consistent with a role in activation of farE expression.
PfarE also has high GC content, which is indicative that a transcriptional activator is needed,
especially considering that S. aureus has high AT content. OfarR overlaps with the promoter of farR
(PfarR) and is downstream of the +1 transcription start site of farE, while OPAL1 bridges the +1
transcription start sites of PfarR and PfarE and overlaps with OfarR. Both the positions OPAL1 and OfarR
would be consistent with a role in autorepression. TFRs usually bind to palindromic repeats as
operator sites, and our lab has previously identified two pseudo-palindromic repeats within the
intergenic segment. PAL1 spans the transcriptional start site of both farR and farE and is located
within OPAL1 while PAL2 is located upstream of PfarE and is located within OfarE. Additionally, the
inverted repeats of PAL1 and PAL2 are juxtaposed. All three operator sites also share a conserved
sequence of TAGWTTA with a TAG sequence central to each operator. This sequence can be
found in both pseudo-palindromes and also in OfarR where it overlaps with the -10 promoter
element TATAGT of PfarR.
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Figure 1.2 Intergenic segment of farER. The farER intergenic segment is 144nt long with three
FarR operator sites within. OfarR overlaps the -10 element of PfarR, OfarE lies downstream of PfarE,
and OPAL1 lies in between. Inverted repeats (IR1, IR2, IR2a) that comprise the pseudopalindromes
(PAL1 and PAL2) are also labeled. Shaded nucleotides highlight a conserved TAGWTTA motif
that is common to each operator site. Figure adapted from Alnaseri et al. (82).

1.6.3 Regulation of farE by FarR
FarR tightly regulates the expression of FarE, which may be to limit the sustained efflux of
resources or endogenously synthesized straight and branched-chain fatty acids. FarR is a type-1
46TFR, and as such, it is divergently transcribed from farE and also expected to repress farE
expression. However, FarR deviates from the typical paradigms of TFRs as it is required for the
activation of farE as it was found that in a farR transposon mutant, farE was unable to be induced
(56). It was also found that farR is subject to autorepression, as typical for a TFR. Of the three
possible operator sites, both OfarR and OPAL1 would be consistent with a role in autorepression, and
we have demonstrated that a G>A point mutation in the TAGWTTA motif of OfarR causes derepression of FarR (82).

Previous studies in our lab have also identified a fatty acid resistant clone of USA300 (FAR7) that
has a single nucleotide polymorphism that corresponds to a H121Y substitution in farR (hereafter
referred to as farR7). The FAR7 clone exhibits greater resistance to uFFA as it can no longer bind
OfarR, causing de-repression of farR, and subsequently increased activation of farE. FarR7 has also
been shown to interact well with OfarE (44, 71). However, this H121Y substitution does not lie in
the N-terminal DNA binding domain, but in the C-terminal ligand-binding domain. It is proposed
that this H121Y amino acid substitution allows FarR7 to mimic ligand-bound conformation,
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allowing FarR7 to better bind to activating operator sites to increase expression of FarE and
subsequent resistance to uFFA.

A defining characteristic of TFRs is that they typically bind a small molecule ligand that modifies
DNA binding. There are reports of other TFRs that bind acyl-CoA, and although arachidonic acid
and linoleic acid are the strongest known inducer of farE expression, their acyl-CoA derivatives
have been shown not to modify FarR DNA binding (82–84). In addition to FarE, the incorporation
of exogenous fatty acids into membrane phospholipids by FakA and FakB1/2 is another
mechanism by which S. aureus utilizes to overcome antimicrobial fatty acids. However, there may
an interplay between FakA and FakB1/2 and FarR and FarE. We have previously determined that
in USA300fakA, farE exhibits an increased basal level of transcription, but cannot be fully
induced (82). As FakA catalyzes the formation of acyl-phosphates, these findings suggest that the
presence of such acyl-phosphates may modify FarR function. It has also been reported that nonesterified fatty acids accumulate within the cytosol of USA300fakA, which may explain the
increased basal level of transcription and the inability to be fully induced (85).

1.7 Hypothesis and Rationale
The goal of this work was to address the nucleotide binding and sensor specificity of FarR. We
have previously shown that mutation in the common TAGWTTA motif of OfarR relieves
autorepression. However, the role of the conserved TAGWTTA motif in OPAL1 and OfarE have not
been identified. Due to the position of OPAL1, we hypothesize that the mutation of this motif or
mutation of PAL1 will lead to de-repression of farR, similar to the de-repression of farR when a
G>A mutation was introduced into the TAGWTTA motif of OfarR. We further hypothesize that the
de-repression of farR through either mutation will lead to an increased activation of farE
expression, and subsequent increased resistance to linoleic acid, as seen in the FAR7 variant.
Additionally, we hypothesize that mutations in the TAGWTTA motif of OfarE will interfere with
FarR binding, leading to decreased resistance to linoleic acid.

16

Furthermore, the role of amino acid substitutions in FarR will be examined, specifically, the role
of cysteine residues in FarR function. FarR contains two cysteine residues, C37 within the Nterminal DNA binding domain and C116 within the C-terminal ligand-binding domain. Cysteine
residues are able to sense changes in the local redox environment of the cell. Arachidonic acid
released from the oxidative burst of immune cells has been shown to kill S. aureus through a lipid
peroxidation mechanism, creating an oxidative environment in the cell. As arachidonic acid as
shown to be the strongest inducer of farE expression, we hypothesize that both cysteine residues
are important for FarR function.

The sensor specificity of FarR also remains to be determined. A defining characteristic of TFRs is
that they typically bind a small molecule ligand that modifies DNA binding affinity, and several
pieces of our data indicate that FarR does the same. FarR7 has previously shown to interact well
with OfarE, a proposed site of activation. The H121Y substitution of FarR7 is located in the Cterminal ligand-binding domain of the protein; however, the N-terminal domain is involved in
DNA recognition and binding, which may indicate that this substitution changes the conformation
of the protein as to mimic a ligand-bound state, allowing it to interact with PAL2. In
USA300fakA, the basal level of farE expression is increased, which may be due to an increased
cellular pool of unphosphorylated fatty acids; however, farE is unable to be fully induced (82).
From these observations, we hypothesize that the physiologic ligand of FarR is acyl-phosphates
and that the binding of FarR to its ligand will modulate the DNA binding affinity allowing FarR
to activate farE through PAL2. Another possibility is that FarR requires a co-activator protein,
which may include FakA or FakB2, similar to DhaS and DhaQ in L. lactis. This work aims to shed
light on the mechanisms by which S. aureus is able to overcome the innate defences of the skin
and to colonize humans which may lead to insights on new therapeutic targets that can prevent
colonization and subsequent infection.
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2 Materials and Methods
2.1 Storage and growth of strains
A list of bacterial strains used or constructed in this study are provided in Table 2.1. Cultures were
maintained as frozen stocks (-80ºC) in tryptic soy broth (TSB) and 20% glycerol. To generate
single colonies, S. aureus strains were streaked onto tryptic soy agar (1.5% Agar) plates
supplemented with chloramphenicol (5 g/mL) when required for plasmid maintenance. E. coli
strains were grown on Luria Bertani (LB) agar or broth supplemented with ampicillin (100 g/mL),
kanamycin (50 g/mL), or chloramphenicol (100 g/mL) when required. Overnight cultures were
generated by inoculating a single colony into a 13 mL polypropylene tube containing 3mL of
media supplemented with antibiotic when needed and grown at 37ºC with shaking at 220 rpm for
18 hours.
Table 2.1 Strains and plasmids used in this study
Strain or Plasmid

Descriptiona

Source or
reference

Strains:
S. aureus:
RN4220

rK− mK+; capable of accepting foreign DNA

(86)

USA300

CA-MRSA, wild-type strain cured of resistance
plasmids

(25)

FAR7

Fatty acid resistance clone 7, single nucleotide
polymorphism H121Y in farR

(56)

USA300farER

USA300LAC with markerless deletion of farE
(SAUSA300_2489) and farR (SAUSA300_2490)

(82)

USA300farER
(pLI50)

USA300ΔfarER with pLI50; Cmr

(82)

USA300farER
(pLIfarER)

USA300ΔfarER complemented with pLIfarER; Cmr

(82)

USA300farER
(pLIfarER1)

USA300ΔfarER complemented with pLIfarER1; Cmr

(82)
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USA300farER
(pLIfarER2)

USA300ΔfarER complemented with pLIfarER2; Cmr

(82)

USA300farER
(pLIfarER3)

USA300ΔfarER complemented with pLIfarER3; Cmr

(82)

USA300farER
(pLIfarER PAL2)

USA300ΔfarER complemented with pLIfarER PAL2;
Cmr

This study

USA300farER
(pLIfarERATG>TAG)

USA300ΔfarER complemented with pLIfarERATG>TAG;
Cmr

This study

USA300farER
(pLIfarERC37A)

USA300ΔfarER complemented with pLIfarERC37A;
Cmr

This study

USA300farER
(pLIfarERC116A)

USA300ΔfarER complemented with pLIfarERC116A;
Cmr

This study

M0049

Clinical isolate, isolated from sputum; FarR C116Y

(87)

M0330

Clinical isolate, isolated from unknown location; FarR
C116Y

(88)

M0390

Clinical isolate, isolated from sputum; FarR C116Y

(89)

M0398

Clinical isolate, isolated from wound; FarR C116Y

(90)

M0423

Clinical isolate, isolated from bronchial washings; FarR
C116Y

(91)

M1545

Clinical isolate, isolated from nares; FarR C116Y

(92)

E. coli:
DH5

λ− ϕ80dlacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1
hsdR17(rK− mK−) supE44 thi-1 gyrA relA1

Invitrogen

BL21 (DE3)

F- ompT gal dcm lon hsdSB (rB- mB+) λ (DE3 [lacI
lacUV5-T7 gene 1 ind1 sam7 nin5])

Novagen

M15[pREP]

F-, Φ80ΔlacM15, thi, lac-, mtl-, recA+, Kmr
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Qiagen

Plasmids:
pLI50

E. coli – S. aureus shuttle vector; AmpR, CmR

(93)

pLIfarE

pLI50 with farE expressed from native promoter;
AmpR, CmR

(56)

pLIfarR

pLI50 with farR expressed from native promoter;
AmpR, CmR

(56)

pLIfarR7

pLI50 with farR gene from variant FAR7 clone; AmpR,
CmR

(56)

pLIfarR1

Mutagenesis of pLIfarR with primers farR1-P and
farR1-M primers; G>A substitution in -10 motif of PfarR;
AmpR, CmR

(82)

pLIfarR2

Mutagenesis of pLIfarR with primers farR2-P and
farR2-M; nucleotide substitutions in PAL1; AmpR, CmR

(82)

pLIfarR3

Mutagenesis of pLIfarR1 with primers farR3-P and
farR3-M; AmpR, CmR

(82)

pLIfarRC37A

Mutagenesis of pLIfarR with primers farR C37A-F and
farR C37A-R; AmpR, CmR

This study

pLIfarRC116A

Mutagenesis of pLIfarR with primers farR C116A-F
and C116A-R; AmpR, CmR

This study

pLIfarRC116Y

Mutagenesis of pLIfarR with primers farR C116Y-F
and farR C116Y-R; AmpR, CmR

This study

pLIfarRATG>TAG

Mutagenesis of pLIfarR with primers farR ATG>TAGF and farR ATG>TAG-R; AmpR, CmR

This study

pLIfarER

farE excised from pLIfarE with KpnI-SacII, and ligated
into KpnI-SacII digested pLIfarR.; AmpR, CmR

(56)

pLIfarER1

As for pLIfarER, except that the KpnI-SacII fragment
was ligated into pLIfarR1; AmpR, CmR

(82)

pLIfarER2

As for pLIfarER, except that KpnI-SacII fragment was
ligated into pLIfarR2; AmpR, CmR

(82)

pLIfarER3

As for pLIfarER, except that KpnI-SacII fragment was
ligated into pLIfarR3; AmpR, CmR

(82)
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pLIfarER4

As for pLIfarER, except that KpnI-SacII fragment was
ligated into pLIfarR4; AmpR, CmR

This study

pLIfarERATG>TAG

As for pLIfarER, except that KpnI-SacII fragment was
ligated into pLIfarRATG>TAG; AmpR, CmR

This study

pLIfarERC37A

As for pLIfarER, except that KpnI-SacII fragment was
ligated into pLIfarRC37A; AmpR, CmR

This study

pLIfarERC116A

As for pLIfarER, except that KpnI-SacII fragment was
ligated into pLIfarRC116A AmpR, CmR

This study

pBAD33

E. coli vector, arabinose inducible; CmR

pBADfakAB2

Native fakA and fakB2 genes cloned in SacI and XbaI
sites of pBAD33; CmR

This study

pQE30

E. coli vector for expression of N-terminal 6His-tagged
fusion proteins; AmpR

Qiagen

pQEfarR

farR open reading frame amplified from USA300 with
primers 6HfarR-F and 6HfarR-R, cloned at SacI and
HindIII sites of pQE30; AmpR

(56)

pQEfarR7

As for pQE-FarR, except that template DNA was from
S. aureus FAR7; AmpR

(56)

pQEfarE-PD

Amplified from USA300 with primers, cloned at
BamHI and SalI sites of pQE30 ; AmpR

This study

(94)

Abbreviations: Ampr – ampicillin resistance, Cmr – chloramphenicol resistance, Kmr –kanamycin
resistance
a
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2.2 DNA Methodologies
2.2.1 Plasmid Isolation from E. coli
All plasmids used in this study are provided in Table 2.1. Plasmid DNA from E. coli was isolated
using the PrestoTM Mini Plasmid Kit (Geneaid) following the manufacturer’s guidelines. Briefly,
3 mL of E. coli at stationary phase were pelleted via centrifugation in a microcentrifuge tube and
then resuspended in 200 L Solution I (50 mM Tris, pH 8.0, 20 mM EDTA, 100g/mL RNaseA).
Cells were then lysed through the addition of 200 L Solution II (200 mM NaOH, 1% w/v SDS)
and then incubated for 2 minutes at room temperature. The solution was then neutralized by the
addition of 300 L Solution III (guanidine hydrochloride with acetic acid) and inverted several
times until a precipitate formed. Samples were centrifuged for 5 minutes at 14,500 x g to pellet the
precipitate. The supernatant was then transferred to a column and centrifuged for 1 minute. 600
L of wash buffer diluted with absolute ethanol was then used to wash the column and was
subsequently centrifuged for 3 minutes to dry the column. Plasmid DNA was eluted into a new
microcentrifuge tube by the addition of 30 L of elution buffer (10 mM Tris, pH 8.5) and
centrifugation at 14,500 x g for 2 minutes.

2.2.2 Plasmid Isolation from S. aureus
Plasmid DNA was isolated from S. aureus using the same protocol for E. coli with the addition of
one step. After the pellet was resuspended in Solution I, 50 g/mL lysostaphin was added. Cells
were then incubated at 37ºC for 30 minutes to allow lysis prior to the addition of Solution II.

2.2.3 Chromosomal Isolation from S. aureus
Chromosomal DNA from S. aureus was prepared using the GenEluteTM Bacterial Genomic DNA
Kit (Sigma) following the manufacturer’s instructions. Briefly, 1.5 mL of S. aureus at stationary
phase was pelleted via centrifugation and resuspended in 200 L of 2.1 x 106 unit/mL solution of
lysozyme supplemented with 50 g lysostaphin. Cells were then incubated at 37ºC for 30 minutes.
20 L proteinase K and 200 L Lysis Solution C was then added and was subsequently vortexed
and incubated at 50ºC for 10 minutes. A GenElute Miniprep Binding Column was prepared with
the addition of 500 L Column Preparation Solution and was then centrifuged at 13,000 x g. The
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lysate was then prepared for binding by the addition of 200 L absolute ethanol, vortexed for 10
seconds, and applied to the Binding Column. The column was then centrifuged at 5,000 x g. 500
L Wash Solution I was then added to the column and centrifuged at 5,000 x g. The column was
then loaded with Wash Solution Concentrate (containing 70% ethanol) and centrifuged for 3
minutes at 13,000 x g. Genomic DNA was eluted into a new microcentrifuge tube by the addition
of 100 L of elution solution to the column and subsequent centrifugation at 5,000 x g for 1 minute.

2.2.4 Restriction Enzyme Digest
All restriction enzymes used in this study were purchased from New England Biolabs (NEB).
Digestions occurred in 25 L volumes and were incubated at 37ºC for 2-4 hours. Digested DNA
was cleaned using GenepHlowTM Gel/PCR Kit (Geneaid) following manufacturer’s instructions.
Briefly, 125 L of Gel/PCR Buffer was added to each digestion reaction. The sample was then
added to a DFH Column and centrifuged at 14,500 x g for 1 minute. 600 L of wash buffer diluted
with absolute ethanol was then used to wash the column and was subsequently centrifuged for 3
minutes to dry the column. DNA was eluted into a new microcentrifuge tube by the addition of 30
L of elution buffer (10 mM Tris, pH 8.5) and centrifugation at 14,500 x g for 2 minutes.

2.2.5 DNA Ligations
DNA ligations were performed with T4 DNA ligase purchased from NEB. DNA fragments were
ligated in 25 L reaction volumes and incubated at room temperature overnight. The 25 L
reaction was composed of 2.5 L 10 x T4 DNA ligase reaction buffer, 1 L T4 DNA ligase (4 x
105 units/mL), and a 3:1 molar ratio of insert to vector.

2.2.6 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used for the separation and visualization of DNA fragments.
Agarose gels (0.8% w/v) were prepared using a 1 × TAE buffer (40 mM Tris acetate, 1 mM EDTA)
supplemented with 1.5 µg/mL ethidium bromide to allow visualization. To run gels, DNA samples
(typically 5 μL) were mixed with loading buffer and loaded into wells in the gel. Electrophoresis
was carried out utilizing a BioRad PowerPac 300 at 110 V for 30-40 minutes. A 1 kb ladder (NEB)
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was utilized to determine DNA fragment size. DNA fragments were visualized using a Syngene
G-Box.

2.2.7 DNA Isolation from Agarose Gels
To isolate specific DNA fragments from restriction enzyme digest, fragments were visualized with
UV light and excised from agarose gel using razor blades. DNA fragments were then cleaned using
GenepHlowTM Gel/PCR Kit following manufacturer’s instructions. Briefly, gel slices were
transferred into a microcentrifuge tube and 500 L of Gel/PCR Buffer was added. Samples were
then incubated at 55-60ºC until gel was completely dissolved. The mixture was then added to a
DFH column and centrifuged for 1 minute at 14,000 x g. Protocol continues as described
previously.

2.2.8 Polymerase Chain Reaction (PCR)
Oligonucleotides used in this study are listed in Table 2.2. PCR reactions were done in 50 L
volumes following protocols outlined by GenScript. A 50 L reaction was composed of 5 L x
Taq buffer containing Mg2+, 1 L, dNTP, 1 L forward primer (100 M), 1 L reverse primer
(100 M), 1 L DNA template (5-100 ng/L), 40.5 L sterile Milli-Q water, and 0.5 L Taq
polymerase (5 units/L). PCRs were carried out utilizing a PTC-100 Programmable Thermal
Controller (MJ Research Inc.) optimized for specific primer annealing temperatures and DNA
fragment lengths.

2.2.9 Nucleotide Sequencing
DNA sequencing was done at the London Regional Genomics facility of the Robarts Research
Institute (London, ON) with samples prepared according to their specifications.

2.2.10 Computer Analyses
Analyses of sequenced DNA and primer design were done utilizing MacVector (MacVector, Inc,
Cambridge, United Kingdom). Protein and DNA BLAST searches were performed utilizing the
National Center for Biotechnology Information website (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
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Table 2.2 Oligonucleotides used in this study
Primer Name
IRD800
OP4.1F
IRD800
OP4.1R
IRD800
OP5.1F
IRD800
OP5.1R
IRD800
OP5.2F
IRD800
OP5.2R
farERIS F
farERIS R
farR PAL2 F
farR PAL2 R
farR ATG>TAG F
farR ATG>TAG R
farR C37A F
farR C37A R
farR C116A F
farR C116A R
farR C116Y F
farR C116Y R
fakA BAD Fa
fakA BAD Ra
fakB2 BAD Fa
fakB2 BAD Rb
farE PD Fc
farE PD Rd
Lower case and

Description
/5IRD800/TGTGTGTAGTTTAATATACAAAAT
/5IRD800/ATTTTGTATATTAAACTACACACA
/5IRD800/TTTAAATATACAGTGTAGATTATTG
/5IRD800/CAATAATCTACACTGTATATTTAAA
/5IRD800/TTTAAATATACAGTGTAAATTATTG
/5IRD800/CAATAATTTACACTGTATATTTAAA
ATGACCGCGGACCATTTATGT
GTACGGTGTACGAGTGCGTT
GAAAATTTTGTATATTAAATTACACACAAAGGAGAAATG
CTCCTTTGTGTGTAATTTAATATACAAAATTTTCCAATTG
CAAAGGAGAAATGTAGTAGAAAGAGACTGATTTAC
CAGTCTCTTTCTACTACATTTCTCCTTTGTGTGTAGTTTAATAT
AC
CAATCAAATTGCCGACAACGCACCTCGTACACCGTAC
GTGCGTTGTCGGCAATTTGATTGACAGTAATCGTTTGG
GTATTAAAAAATGTCGCCATTAAAATTATGCATAACGATATC
GCATAATTTTAATGGCGACATTTTTTAATACTTTATTAAATTC
GTATTAAAAAATGTCTATATTAAAATTATGCATAACGATAT
GCATAATTTTAATATAGACATTTTTTAATACTTTATTAAATTC
gtgaataatacaggcaagagctcTTAGGAGGACAACTTGAAATGATTAGC
aattagagctgTTAATGATGATGATGATGATGTTCTACTGAAAAGAA
ATATTGATAAATTGGT
cacatacctttctacattgagctcGTAAAAAATAAGGGGGAAAACGACC
ctcctctatctagaTAATTATAAATTTAGTCTATAAAGGATTGAAATG
G
ggatagtgattgtagctggatccTTGATACCACTTGCTACAAATGCACCG
gcaacaataataccaactagtcgacAATTACCGCCTACTTCTGTAGATGTC
bold nucleotides indicate the addition of 5´sequences to incorporate restriction

endonuclease cut sites as follows: aSacI, bXbaI cBamHI, and dSalI. Nucleotides in bold and
underlined show the locations of site-directed mutations.
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2.3 Transformation Methodologies
2.3.1 Preparation of Transformation Competent E. coli
CaCl2 competent E. coli DH5 or BL21 (DE3) were prepared for transformation following an
established lab protocol. Briefly, stationary phase E. coli DH5 was inoculated into 400 mL LB
to an OD600 of 0.01. When the culture reached mid-exponential phase (OD~0.5), it was placed on
ice for 20 minutes. The culture was then pelleted at 4,000 x g at 4ºC for 10 minutes, and cells were
subsequently washed through resuspension with 100 mL 0.1M CaCl2, 15% glycerol (v/v, and then
left on ice for 30 minutes. Cells were pelleted again via centrifugation and pellet was resuspended
in 4 mL 100 mL 0.1M CaCl2, 15% glycerol (v/v) for aliquoting into 100 L volumes. Competent
cells were flash-frozen and placed in an -80ºC freezer for storage.

2.3.2 Transformation of Competent E. coli
CaCl2 competent E. coli DH5 or BL21 (DE3) were transformed with plasmid prepared via
techniques described previously. 5 L plasmid or 10 L ligation mixture was added to an aliquot
of thawed competent cells and incubated on ice for 30 minutes. Cells were then heat shocked at
42ºC for 90 seconds, followed by a 2 minutes incubation on ice. 500 L of LB was then added to
the cells, which were then resuscitated for 1 hour at 37ºC. Cells were then plated on LB agar
containing relevant antibiotics. Plates were grown overnight and examined for single colonies the
next day.

2.3.3 Preparation of Transformation Competent S. aureus
Electro-competent S. aureus (RN4220, USA300, and USA300 derivatives) were prepared for
transformation using established lab protocols. Briefly, stationary phase S. aureus cells were
inoculated into 400 mL TSB to an OD600 of 0.01. When the culture reached mid-exponential phase
(OD~0.5), it was placed on ice for 10 minutes. The culture was then pelleted at 4,000 x g at 4 ºC
for 10 minutes, and cells were subsequently washed through resuspension with 40 mL ice-cold 0.5
M sucrose, and then left on ice for 20 minutes. Cells were pelleted via centrifugation, resuspended
in 5 mL 0.5 M sucrose and centrifuged again. The pellet was then resuspended in 4 mL 0.5 M
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sucrose for aliquoting into 100 L volumes. Competent cells were flash-frozen and placed in an 80ºC freezer for storage.

2.3.4 Transformation of Competent S. aureus
Electro-competent S. aureus cells were transformed with plasmid DNA isolated from other cells.
RN4220 is a restriction endonuclease deficient strain, and therefore can be transformed with
plasmid DNA from E. coli. USA300 and USA300 derivates were transformed with plasmid DNA
isolated from RN4220 or USA300 strains. 3 L of plasmid DNA was added to an aliquot of thawed
electro-competent cells and incubated on ice for 30 minutes. Cells were then transferred to a cold
2 mm electroporation cuvette (VWR) and electroporated using a BioRad Gene Pulser II set to 2.5
kV, 200 Ω, and 25 μF. Electroporated cells then received 900 L TSB and were left to resuscitate
for 1 hour at 37ºC. Cells were then plated on TSA containing relevant antibiotics. Plates were
grown overnight and examined for single colonies.

2.4 Mutagenesis and DNA Cloning Methods
2.4.1 Construction of pLIfarER Derivative Plasmids
To construct pLIfarER with various mutations, mutations were first made in pLIfarR with the
appropriate primers (Table 2.2). The complementation construct pLIfarR was modified using the
mutagenic primers farR PAL2-F and farR PAL2-R, using protocols and reagents following the
QuikChange Site-Directed Mutagenesis Kit (Stratagene), to construct pLIfarR4, harboring a single
G>A nucleotide substitution within the TAGWTTA motif of PAL2. The same protocol was used
to construct pLIfarRATG>TAG, pLIfarRC37A, pLIfarRC116A, and pLIfarRC116Y using mutagenic
primers farR ATG>TAG F and farR ATG>TAG R, farR C37A F and farR C37A R, farR C116A
F and farR C116A R, and farR C116Y F and farR C116Y R, respectively. The plasmids were then
sent for sequencing at Robarts Research Institute (London, ON) to confirm the integrity of the
insert. The farER locus was then reconstituted. Briefly, pLI50 with a farE insert that was
previously constructed was digested with Kpn1 and SacII. The digestion mixture was then
separated on an agarose gel and the 2.5 kb restriction fragment containing farE was then purified.
The pLIfarR plasmids containing the desired mutations were also cut with KpnI and SacII and
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farE was then ligated into pLIfarR. The reconstituted plasmid was then transformed into E. coli
DH5α, and later S. aureus RN4220 and USA300 target strains following standard protocols.

2.4.2 Construction of Recombinant Plasmids
To construct pQEfarE-PD recombinant plasmids, primers were designed according to the porter
domains sequence of farE. The porter domain was amplified using primers farE-PD F and farEPD R. The resulting PCR product was cleaned up and digested with BamHI and SalI and ligated
into BamHI-SalI digested pQE30. The resulting construct was transformed into E. coli M15/pREP
and colonies were screened on media supplemented with appropriate antibiotics. Positive colonies
were confirmed by restriction digest and sequencing. To construct pBADfakAB2 primers fakA
was first amplified using primers fakA BAD F and fakA BAD R. These primers were also modified
to incorporate a C-terminal histidine tag. The resulting PCR product was cleaned up and digested
with enzymes and ligated into pBAD33 that had been cut with the same enzymes. The resulting
construct was transformed into E. coli DH5 and colonies were screened on media supplemented
with appropriate antibiotics. Positive colonies were confirmed by restriction digest and
sequencing. fakB2 was then amplified using primers fakB2 BAD F and fakB2 BAD R. The
resulting PCR product was digested with and ligated into pBADfakA that had been digested with
the same enzymes. Protocol was continued as mentioned previously.

2.5 Protein Methodologies
2.5.1 SDS-PAGE
Proteins were assessed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE). Samples were prepared and resuspended in 10 L 1 x Laemmli loading buffer (4 x buffer:
240 mM Tris-Cl pH 6.8, 8% w/v SDS, 40% glycerol v/v, 20% -mercaptoethanol, 0.01%
bromophenol blue and Milli-Q water). The entire sample and a pre-stained protein ladder (NEB)
were loaded onto a 12% bis-acrylamide gel and run at 100 V for 90 minutes. The gel was then
stained for 18 hours with Coomassie blue stain for visualization or transferred onto a membrane
for Western blotting. Stained gels were destained with destaining solution (40% methanol, 10%
acetic acid in dH2O by volume).
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2.5.2 Mass Spectrometry
Protein identification was achieved through mass spectrometry at the UWO MALDI MS Facility
(London, ON). Proteins were separated by SDS-PAGE and stained with Coomassie blue as
previously described. Proteins of interest were picked using an EttanTM spot picker. Samples were
digested with trypsin and analysed using an AB SCIEX TOF System.

2.5.3 Expression and Purification of Recombinant Protein
Recombinant 6xHis-FarR, 6xHis-FarR7 or 6xHis-FarE-PD was purified from E. coli m15/pREP.
Cultures were grown in 500 mL LB supplemented with 100 g/mL ampicillin and 50 g/ml
kanamycin at 37oC with shaking. When an OD600~0.5 was reached, 0.1 mM IPTG was added, and
the culture was grown with shaking at room temperature overnight. Cells were then collected via
centrifugation at 4,000 x g for 20 minutes at 4ºC and resuspended in 20 mL binding buffer (0.5 M
NaCl, 20 mM sodium phosphate pH 7.4, 20 mM imidazole). Cells were then lysed using a cell
disruptor (Constant Systems Ltd.) at 30 psi and then centrifuged for 20 minutes at 4ºC and 11,000
RCF in a Beckman Coulter Optima L-900K ultracentrifuge to remove debris. The lysate was then
filtered using a 0.45 m Acrodisc syringe filter (Pall Laboratory) and applied onto a 1 mL HisTrap nickel affinity column (GE Healthcare) that had been equilibrated with binding buffer.
Recombinant proteins were eluted over an imidazole gradient of 0.1 M to 0.5 M in 20 mM sodium
phosphate pH 7.4. The fractions were subject to SDS-PAGE to determine purity. Fractions
containing 6xHis-FarR and 6xHis-FarR7 were pooled and dialyzed in 0.15M NaCl 20 mM sodium
phosphate pH 7.4 at 4ºC. 6xHis-FarE-PD was further purified via anion exchange chromatography
using a Resource Q column after being dialyzed into 20 mM Tris pH 7.4. Fractions were subject
to SDS-PAGE to confirm purity and protein was pooled and dialyzed into 0.15 M NaCl and 20
mM sodium phosphate pH 7.4.

2.5.4 Western Blot
Rabbit polyclonal antisera recognizing FarR and FarE-PD were generated by ProSci Incorporated
(Poway, CA, USA). For blots with FarR antisera, single colonies of E. coli DH5 transformed
with pLI50, pLIfarR, pLIfarER, and derivatives were inoculated in 3 mL LB supplemented with
appropriate antibiotic and incubated for 8 hours at 37ºC with shaking at 200 rpm. Cultures were
then subcultured at an OD600 of 0.01 into 25 mL LB with antibiotics and grown overnight. Cells
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were then pelleted via centrifugation at 4,000 x g for 10 minutes, and cells were washed with 1 x
PBS. Cells were pelleted again and resuspended in 5 mL lysis buffer (150 mM NaCl, 5 mM EDTA
pH 8.0, 50 mM Tris-HCl pH8.0, 1% v/v Triton X-100, 0.5% v/v SDS), supplemented with EDTAfree protease inhibitor and incubated at room temperature with agitation. The sample was then
centrifuged at 4,000 x g for 20 minutes at 4ºC and supernatant was collected. Protein concentration
was determined by Bradford assay. 25 g of protein sample was mixed with 10 L 1 x Laemmli
buffer and was boiled at 100ºC for 5 minutes followed by centrifugation at 14,500 x g for 1 minute.
The entire sample was subject to SDS-PAGE using a 12% bis-acrylamide gel, after which proteins
were transferred to a PVDF membrane in a system submerged in transfer buffer (3.03 g Tris, 14.4
g glycine, 200 mL methanol, 800 mL dH2O). The membrane was blocked overnight with blocking
buffer (1 g skim milk powder, 20 mL 1 x PBS) at 4ºC. The membrane was then incubated in 25
mL of primary antibody diluted 1000-fold in antibody dilution buffer (PBS containing 0.1%
Tween20 and 2% w/v skim milk powder) and incubated at 4ºC for 1 hour. The membrane was then
washed 3 times with PBS-Tween. The membrane was then incubated for 1 hour at 4ºC in 25 mL
of 5000-fold diluted secondary antibody (IRDye800-conjugated goat anti-rabbit IgG; Jackson
Immunoresearch Laboratories Inc.) diluted in antibody dilution buffer. Membranes were washed
an additional 3 times with 1 x PBS-tween and were then imaged using Odyssey imager (LI-COR
Biosciences)

2.6 Growth Analyses
For growth assays, inoculum cultures were supplemented with antibiotic where required, and these
cultures were then inoculated into TSB that lacked antibiotics to assess growth in the presence of
antimicrobial fatty acids. When supplementing media with fatty acid, a 5 mM stock was initially
prepared in TSB with 1% DMSO. This stock was then diluted into flasks containing TSB at a 1:5
ratio of medium volume to flask size with 0.1% DMSO to achieve the desired concentration of
fatty acid. Cultures were then inoculated to an initial OD600 of 0.01. Samples were withdrawn at
hourly intervals for the determination of the OD600. All cultures were grown in triplicate or as
specified in individual figure legends.
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2.7 EMSA
IRDye800-labeled single-stranded probes were purchased from IDT (Table 2.2). Complementary
oligonucleotides were annealed at 100 M each in 10 mM Tris pH 8.0, 0.1 mM EDTA, incubated
at 95oC for 5 minutes and allowed to cool at room temperature for 45 minutes. These probes were
then used in EMSA reactions in a total 25 L consisting of 5 L EMSA buffer (20% glycerol, 30
mM Tris-HCl pH 8.0, 1 mM MnCl2, 120 mM KCl, 1 mM MgCl2, 16 mM DTT), 240 g/mL BSA,
15.2 g/mL poly[d(I-C)], 5 pmol of probe, and up to 2 M recombinant 6xHis-FarR or 6xHisFarR7. The reaction was incubated at room temperature for 60 minutes, after which they were run
on a 6% TBE-acrylamide gel at 120 V for 45 minutes and imaged using Odyssey imager (LI-COR
Biosciences). For EMSA conducted using the 339 bp farER intergenic segment, PCR products
were amplified as described above, using 5 pmol of PCR product, and after electrophoresis, the
EMSA gel was stained with 3 g/mL prior to imaging using Syngene G-Box.
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3 Results
3.1 Evaluation of Nucleotide Substitutions in FarR DNA Operator sites
3.1.1 Mutations in OfarR and OPAL1 relieve autorepression but do not cause
increase in resistance to linoleic acid
Our lab has previously identified three operator sites for FarR within the intergenic segment (Fig.
1.2). These include OfarR which overlaps with PfarR, OPAL1 which overlaps both PAL1 and PfarR, and
OfarE which lies upstream of PfarE. Additionally, all three operator sites contain a common motif of
TAGWTTA. The positions of both OfarR and OPAL1 are consistent with a role in auto-repression,
and we have previously shown that a G>A substitution in the conserved TAGWTTA motif of
OfarR, alleviates autorepression of farR (82). To support this finding, we wanted to determine
whether this mutation in OfarR, hereafter referred to as pLIfarER1 and mutations in OPAL1 cause a
decrease in the binding of these operator sites (Fig 3.1A). Mutations were made in the inverted
repeats of OPAL1, hereafter referred to as pLIfarER2 and EMSA were done with the entire
intergenic segment containing these mutations (Fig 3.1B). EMSA done with WT FarR and the
native IS displays three discrete mobility shifts designated S1, S2, and S3, consistent with there
being three operator sites OfarR, OPAL1, and OfarE. When EMSA was conducted with the farER1-IS,
the S2 shift was eliminated indicating that this corresponds to FarR binding to the OfarR site.
However, when EMSA was conducted with the farER2IS, both the S1 and S2 shifts were
eliminated. This suggests that FarR binds preferentially to OPAL1 and the secondarily to OfarR, since
both the S1 and S2 shifts were eliminated with nucleotide substitutions in the OPAL1 site of the
farER2 construct. By default, these observations imply that the S3 supershift is due to FarR binding
to OfarE, since this site is not affected in the farER2 construct. In support of this conclusion, EMSA
with the farER3IS construct harboring substitutions in both OfarR and OPAL1 still yielded the S3
shift.

Western blots for the detection of FarR were then performed using lysates of E. coli DH5⍺
transformed with pLIfarER derivatives, to evaluate how these substitutions affected autorepression
of FarR expression (Fig 3.1C). We found that mutations made in both OfarR and OPAL1 caused an
increased amount of FarR present in lysates. More FarR was detected with constructs harbouring
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mutations in OPAL1 compared to those where only OfarR was affected, which is consistent with our
finding that the binding of OfarR is dependent on OPAL1. Previous experiments in our lab have also
discovered FAR7, a variant strain of USA300 that demonstrates increased resistance to linoleic
acid due to a H121Y substitution in FarR. This substitution causes FarR7 to not be able to bind to
OfarR, but it is able interact well with OfarE as shown by EMSA (Fig 3.1B). This relief of autorepression increases the resistance to uFFA due to increased expression of farE, even without the
addition of uFFA. We therefore hypothesized that the abrogation of binding to OfarR and OPAL1
should increase resistance to linoleic acid due to the increased production of FarR. However, we
found that mutations in both OfarR and OPAL1 decrease resistance to uFFA, even though these
mutations cause strong de-repression of farR expression (Fig 3.1D). Therefore, constitutive
expression of wild type FarR was unable to promote increased resistance to antimicrobial uFFA,
which is uniquely associated with the H121Y variant in FarR7.
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Figure 3.1 Mutations in OfarR and OPAL1 relieve autorepression but do not cause an increase
in resistance to linoleic acid. (A) Nucleotide sequence showing the variable segments of the
144bp farERIS, farER1IS, farER2IS, and farER3IS probes containing nucleotide substitutions in OfarR
(pLIfarER1, PAL1 (pLIfarER2), or OfarR and PAL1 (pLIfarER3). The labeled features above
farERIS are as detailed for Fig. 2A. The larger bold type “T” in IR1 indicates the +1 transcription
start site of farR. Lowercase underlined nucleotides indicate nucleotide substitutions that
differentiate each probe. (B) EMSA was conducted with 5 pM probe and 0, 0.5, 1, or 2 µM FarR
or

H121Y

FarR, as indicated. The first lane of each panel represents electrophoresis of the farERIS

probe without added protein (i.e., 0 µM FarR). In the upper-left panel, the protein-DNA complexes
S1, S2, and S3 are labeled. Protein-DNA complexes were directly imaged by ethidium bromide
staining. (C) Western blot of gel loaded with 25 ng of purified 6xHis-FarR or 25 µg of cell lysate
protein from E. coli DH5⍺ transformed with pLI50 vehicle, pLIfarR, or pLIfarER and derivatives.
(D) Growth of USA300ΔfarER complemented with pLI50 vehicle or pLIfarER and derivatives in
TSB plus 50 µM linoleic acid. Each data point represents the mean and standard deviation of the
results from triplicate cultures.
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3.1.2 Mutations in PAL2 cause a loss of resistance to linoleic acid
We have shown that mutations in the common TAGWTTA motif of both OfarR and mutations in
PAL1 of OPAL1 cause a loss of autorepression of farR (Fig 3.1B) (82). However, the role of the
TAGWTTA within the potentially activating OfarE operator site has not been elucidated. OfarE lies
upstream of PfarE and contains PAL2 which is composed of IR1 and IR2a (Fig. 1.2). Additionally,
the common TAGWTTA motif lies within. Since a G>A nucleotide substitution in the TAGWTTA
motif of OfarR abrogated FarR binding (Fig. 3.1B), we hypothesized that a G>A substitution in the
TAGWTTA motif of PAL2, would likewise abrogate binding to this potentially activating site,
and subsequently cause a loss in resistance to linoleic acid. This G>A mutation in the TAGWTTA
motif of OfarE was introduced into pLIfarER constituting the pLIfarER4 construct, which was
subsequently transformed into USA300farER for growth analyses (Fig 3.2A). Accordingly, we
found that the elimination of the conserved binding sequence does cause a loss of resistance to
linoleic acid. EMSA were then done using probes of the native farERIS, and the farER4IS
harbouring the G>A substitution in the TAGWTTA motif of PAL2 (Fig 3.2B). Surprisingly, the
mobility shift pattern was not altered, as S3 was still visible when PAL2 was mutated, indicating
that FarR can still bind to OfarE even when the TAGWTTA motif is altered. However, even though
FarR can still bind to OfarE when the TAGWTTA motif is altered, there is still a loss of resistance
to linoleic acid.
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Figure 3.2 Mutations in PAL2 cause a loss in resistance to linoleic acid. (A) Growth of USA300
ΔfarER complemented with pLI50 vehicle or pLIfarER and derivatives in TSB plus 50 µM linoleic
acid. Each data point represents the mean and standard deviation of the results from triplicate
cultures. (B) EMSA was conducted with 5 pM of WT farERIS or PAL2G>A farER4IS probe and 0,
0.5, 1, or 2 µM FarR. The first lane of each panel represents electrophoresis of the farERIS probe
without added protein (i.e., 0 µM FarR). In the upper-left panel, the protein-DNA complexes S1,
S2, and S3 are labeled. Protein-DNA complexes were directly imaged by ethidium bromide
staining.
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3.1.3 Significance of the TAGWTTA motif is context dependent
When EMSA were done with the entire intergenic segment, FarR was able to bind to both OPAL1
and OfarE, as shown by shifts S1 and S3, respectively (Fig. 3.1 B). However, when the OfarE site
was altered and EMSA was conducted with the resulting farER4IS, the S3 shift remained evident.
We therefore conducted additional EMSA to assess the specificity of FarR binding to a probe
containing the minimal PAL1 and PAL2 segments, both of which contain the common
TAGWTTA motif. Additionally, as we have previously shown that a G>A substitution in the
TAGWTTA motif of OfarR abrogated binding, we wanted to determine if a similar G>A mutation
in the PAL1 TAGWTTA would do the same (82). EMSA were done with minimal PAL1 or PAL2
probes that were both extended by 4 nucleotides at each end (Fig 3.3A). FarR was able to bind to
a minimal PAL1 probe, as well as to a minimal PAL1 probe with a G>A in the TAGWTTA, albeit
to a lesser extent (Fig 3.3B). However, FarR was unable to interact with a minimal PAL2 probe
compared to the S3 supershift of the entire intergenic segment probe (Fig 3.1B). It is important to
note that PAL1 and PAL2 are composed of similar or identical inverted repeat half sites (IR1 and
IR2/2a), with their positions in PAL2 being juxtaposed relative to PAL1. Therefore, although both
PAL1 and PAL2 contain the common TAGWTTA motif, FarR exhibits differential binding to
these sites, recognizing a probe containing the minimal PAL1 segment, but not PAL2. From these
observations, we are not able to conclude that the S3 shift observed in EMSA is due to specific
binding of FarR to PAL2.
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Figure 3.3 Significance of the TAGWTTA motif is context dependent. (A) Composition of
PAL1 (OP5.1) and PAL2 (OP4.1) probes. Nucleotides comprising the inverted repeat IR1, IR2,
and IR2a components of PAL1 and PAL2 are underlined. The IR1 half-site is shaded, while the
IR2 and IR2a half-sites are in bold type. Probe OP5.2 is identical to OP5.1, with the exception of
a G>A substitution in the TAGATTA motif that overlaps IR2. The top strand contains a 5’ IRDye
800 addition. (B) EMSA with 0, 0.2, or 0.5 µM FarR mixed with 5 pM OP5.1, OP5.2, or OP4.1,
as indicated.
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3.2 Investigation into farR leader mRNA
3.2.1 Resistance to linoleic acid is not mediated by farR leader mRNA itself
There are examples of some TFRs that utilize RNA-mediated post-transcriptional mechanisms to
regulate the target gene. In Mycobacterium smegmatis AmtR is a global regulator of nitrogen
metabolism. When nitrogen is abundant, cis-encoded small RNAs (sRNA) complementary to amtR
mRNA blocks transcription (95). LuxR, a TFR in Vibrio harveyi is also regulated by sRNAs by
complementary base pairing to the 5UTR (96). Additionally, sRNAs often target the 5UTR of
mRNA. The farR mRNA has a 105bp long 5UTR that may be target for sRNA, or other
mechanisms of RNA mediated regulation, such as riboswitches. Moreover, the 5 ends of farE and
farR mRNA overlap through 21nt that could have a negative impact on the stability or translation
and could promote degradation through dsRNA ribonucleases. To determine if the 5UTR of farR
was responsible for the activation of farE itself in the absence of FarR protein, the start codon of
farR was mutated to a stop codon. FarR was only slightly detected in E. coli lysates harbouring
pLIfarRATG>TAG, indicating that this mutation did appear to stop the majority of farR translation
(Fig 3.4A). USA300ΔfarER complemented with pLIfarERATG>TAG was unable to grow in 50 µM
linoleic acid indicating that the farR 5UTR mRNA is not in itself sufficient to promote resistance
to linoleic acid and confirming that functional FarR protein is required for expression of FarE (Fig
3.4B).
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Figure 3.4 Resistance to fatty acid is not mediated by farR leader mRNA itself. (A) Western
blot of gel loaded with 25 ng of purified 6xHis-FarR or 25 µg of cell lysate protein from E. coli
DH5⍺ transformed with pLI50 vehicle, pLIfarR, and pLIfarRATG>TAG. (B) Growth of USA300
ΔfarER complemented with pLI50 vehicle or pLIfarER and derivatives in TSB plus 50 µM linoleic
acid. Each data point represents the mean and standard deviation of the results from triplicate
cultures.
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3.3 Role of cysteine residues in FarR function
3.3.1 Mutation of cysteine residues result in loss of resistance to linoleic acid
Other regulators in S. aureus, like SarA, use the oxidation of cysteine residues to modulate DNA
binding and regulation. SarA regulates many genes both directly and indirectly including
hemolysins, fibronectin and fibrinogen binding proteins, enterotoxins as well as trxB. TrxB
maintains TrxA, thioredoxin, in a reduced form allowing it to maintain the intracellular thioldisulfide balance. The oxidation of Cys9 in SarA has been shown to reduce the binding of SarA to
the promoter of txrB (97). Arachidonic acid (20:4), a polyunsaturated free fatty acid, is released
from macrophages during the oxidative burst and has been shown to kill S. aureus through lipid
peroxidation, creating an oxidative environment in the cell (48). This is of importance as our lab
has previously shown arachidonic acid as the strongest known inducer of farE expression (56).
Therefore, we wondered whether cysteine residues were important in FarR function.

FarR contains two cysteine residues. Cys37 lies within the N-terminal DNA binding domain and
is conserved in all FarR proteins in S. aureus. Cys116 lies within the C-terminal ligand binding
domain and is not as conserved as Cys37 (Fig 3.5A). Site directed mutagenesis was done, using
pLIfarER as a template, to mutate either cysteines to an alanine residue. The mutated pLIfarER
plasmids were then used to complement USA300farER and susceptibility to linoleic acid was
determined (Fig 3.5B). We found that the mutation of either cysteine was sufficient to eliminate
resistance to linoleic acid. As previously mentioned, mutations in OfarR and OPAL1 relieve
autorepression and cause an increased amount of FarR present in lysate. However, this increase in
FarR levels causes a decrease in the resistance to linoleic acid. As Cys37 lies within the DNA
binding domain of FarR, we wondered whether Cys37 could be involved in DNA binding and
autorepression. If Cys37 is involved in the autorepression of farR, the introduction of an alanine
residue in this position could relieve autorepression, leading to increased levels of FarR and could
explaining the decrease in resistance to linoleic acid. Western blots for detection of FarR were
done in E. coli lysates transformed with pLIfarR C37A or C116A. These Western blots revealed a
decreased amount of C116AFarR relative to WT FarR (Fig 3.5C). Interestingly, there was a complete
absence of C37AFarR, indicating that this mutation may cause super-repression of farR.
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Figure 3.5 Cysteine residues are necessary for FarR function. (A) Structure of FarR
homodimer. Orange represents N-terminal DNA binding domain. Pink represents ligand binding
domain. Both cysteine-37 and cysteine-116 are labeled in blue. (B) Western blot of gel loaded with
25 ng of purified 6xHis-FarR or 25 µg of cell lysate protein from E. coli DH5⍺ transformed with
pLI50 vehicle, pLIfarR, and pLIfarR derivatives. (C) Growth of USA300 ΔfarER complemented
with pLI50 vehicle or pLIfarER and derivatives in TSB plus 50 µM linoleic acid. Each data point
represents the mean and standard deviation of the results from triplicate cultures.
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3.4 Assessing influence of amino acid variation in FarR sequence
3.4.1 C116Y substitution causes increase in production of FarR compared to
C116A
As mentioned previously, FarR7 (H121YFarR) exhibits increased expression of both farR and farE,
even in non-inducing conditions and therefore, an increased resistance to linoleic acid.
Additionally, a recent study found that a C116R substitution in FarR causes constitutive activation
of farE (98). C116 and H121 are in close proximity and both lie within the same alpha helix in the
ligand binding domain of FarR. Therefore, we wondered whether a C116Y substitution would
cause a similar phenotype to both the H121Y and C116R mutants in which farE is constitutively
expressed. Western blots for detection of FarR in E. coli lysates transformed with pLIfarR H121Y
or pLIfarR C116Ywere done and we found that levels of
that of

C116A

FarR (Fig 3.6). However, levels of

C116Y

C116Y

FarR were increased compared to

FarR was not as abundant as

H121Y

FarR and

was more comparable to that of WT FarR. It remains to be determined if this C116Y mutant causes
an increase in resistance to linoleic acid.

43

Figure 3.6 Role of tyrosine in the ligand-binding domain of FarR. Western blot for detection
of FarR. Gel was loaded with 25 ng of purified 6xHis-FarR or 25 µg of cell lysate protein from E.
coli DH5⍺ transformed with pLI50 vehicle, pLIfarR, and pLIfarR derivatives.
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3.4.2 S. aureus

C116Y

FarR clinical isolates have variable resistance to linoleic

acid
We have determined that a C116Y substitution in FarR increases the abundance of FarR found in
E. coli lysates compared to that of a C116A substitution, albeit not to the same extent as a H121Y
substitution. It has been previously established that this H121Y substitution in FarR causes
constitutive expression of farE, leading to resistance to linoleic acid. In contrast, USA300farER
complemented with pLIfarERC116A is unable to grow in 50  linoleic acid. As it appears that
increased abundance of

H121Y

FarR protein leads to increased resistance, we speculated that the

C116Y substitution may likewise promote increased resistance to linoleic acid. When BLAST
analysis was conducted to compare the FarR protein of S. aureus USA300 to all other S. aureus
genome sequences, over 3000 strains have a cysteine at position 116. However, 11 strains have a
tyrosine at position 116, all of which are MRSA (Table 3.1). Some of these strains were grown in
TSB supplemented with 50 M linoleic acid to determine whether they were resistant to fatty acid,
similar to the FAR7 strain. Out of the 6 that we were able to test, 2 clinical isolates appear to be
more resistant to linoleic acid (M0330 and M1545) (Fig 3.7 A and B). M0390 appears to be
somewhat resistant to linoleic acid, but not to the extent that M330 and M1545 are. Further
characterization of these clinical isolates needs to be done, including sequencing to confirm the
C116Y substitution, as well as to determine if there are additional mutations that may account for
the increased resistance to linoleic acid as seen here.
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Table 3.1 Clinical isolates of S. aureus C116YFarR
Strain

Location of Isolation

M0049

Sputum

M0182

Unknown

M0194

Sputum

M0330

Unknown

M0374

Blood

M0377

Sputum from endotrachea

M0390

Sputum

M0398

Wounds

M0402

Nares

M0423

Bronchial Washings

M01545

Nares

Figure 3.7 Growth of S. aureus

C116YFarR

clinical isolates in linoleic acid. (A)(B) Growth of

USA300, FAR7 and indicated clinical isolates in TSB plus 50 µM linoleic acid. Each data point
represents the mean and standard deviation of the results from triplicate cultures.
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3.5 Assessing the Role of acyl-phosphates for the activation of farE expression
3.5.1 Co-expressing fakAB2 and farER in Escherichia coli
One tenet of TFR function is the ability of a ligand to modulate the DNA binding affinity of the
TFR, enabling it to repress or activate transcription of the regulated gene. However, the
physiological ligand of FarR remains unknown. A previous study in our lab has observed that in
USA300fakA, farE is unable to be fully induced (82). As mentioned previously, FakA is a kinase
that catalyzes the first step in the incorporation of exogenous fatty acids into membrane
phospholipids (58). Therefore, we hypothesize that the identity of the ligand may be an acylphosphate. To test this hypothesis, we co-expressed fakA and fakB2 in E. coli under the expression
of the arabinose inducible pBAD33 promoter. fakA was cloned under control of the pBAD
promoter with fakB2 cloned in directly after. FakB2 was chosen over FakB1 as FakB2
preferentially binds unsaturated fatty acids. Concurrently, E. coli was transformed with pLIfarER
containing farE and farR expressed from their native promoters. If our hypothesis is correct,
induction of fakAB with arabinose will lead to production of an acyl-phosphate, which in turn will
be bound by FarR, and lead to the induction of farE (Fig. 3.8A). We chose to approach this
experiment in a heterologous host, as if successful, it would elucidate the minimal combination of
genes necessary to induce farE expression.

First, E. coli DH5 transformed with pBADfakAB2 was induced with arabinose to confirm the
production of FakA and FakB2(Fig 3.8B). The identities of both proteins were confirmed via mass
spectrometry analysis. To determine whether the presence of FakAB2 and phosphorylated fatty
acids increase the expression of FarR, Western blots for detection of FarR were done on E. coli
lysates grown in LB with the addition of 50 M LA and 0.1% L-arabinose when stated to induce
fakAB2 expression. E. coli does produce palmitoleic and oleic acid as endogenous fatty acids,
however, previous work has shown that these uFFA do not induce farE expression as strongly as
linoleic or arachidonic acid (56,99); therefore linoleic acid was added to the cultures. Lysates of
DH5 harbouring pLIfarR1, in which farR is de-repressed, was used as a positive control. There
appears to be a similar amount of FarR present when co-expressed with fakAB2 compared to
pLIfarER but not compared to lysates harbouring pLIfarR1, in which FarR is de-repressed (Fig
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3.8C). This indicates that, if acyl-phosphates were generated, their presence does not directly
influence the abundance of FarR in the lysate. However, it is unknown whether the presence of
both FakAB2 and phosphorylated fatty acids influence the amount of farE present in lysates.
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Figure 3.8 Co-expression of fakAB2 and farER in E. coli DH5. (A) Schematic of experimental
design. 1% L-arabinose and 50 M linoleic acid were added to E. coli cultures at OD600 ~ 0.5.
Cells were grown for an additional 2 hours before being lysed for Western blots. (B) SDS-PAGE
of E. coli DH5⍺ lysate harbouring pBADfakAB2 or empty vector. Cultures were induced at midexponential phase with 0.1% L-arabinose and grown for 2 hours. (C) Western blot for detection
of FarR. Gel was loaded with 5 g of purified 6His-FarR or 25 g of cell lysate protein from DH5⍺
transformed with indicated plasmids.
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3.5.2 Production of anti-FarE-PD antibodies
In order to detect the presence of FarE in E. coli co-expressing both FakAB2 and FarER, we set
out to generate anti-FarE antibodies. Previous attempts to generate anti-FarE antibodies against
the C-terminal coiled coil domain of FarE were unsuccessful, possible due to the tendency of the
recombinant protein to precipitate. Porter domains of RND-family efflux pumps, which are
responsible for substrate recognition and binding, are soluble. Therefore, we chose to purify a
porter domain of FarE (FarE-PD) for antibody production (100). farE-PD was cloned into pQE30
and purified via metal affinity chromatography and was further purified using anion exchange
chromatography (Fig 3.9A and B). However, it was difficult to purify large amounts of FarE-PD,
and the amount that was purified degraded very quickly, degrading after only one freeze-thaw
cycle (Fig 3.9C). Nonetheless, what was purified was sent for polyclonal antibody production in
New Zealand white rabbits. The anti-FarE-PD antibodies were able to recognize purified FarE-PD
on a Western blot (Fig 3.9D). However, we were unable to identify whole FarE protein from either
E. coli harbouring farE on an inducible plasmid, or USA300 grown in the presence of linoleic acid.
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Figure 3.9 Production of anti-FarE-PD antibodies. (A) Cell lysate was applied onto a 1 mL
His-Trap nickel affinity column that was equilibrated with binding buffer (20 mM sodium
phosphate, 0.5 M NaCl, 20 mM imidazole, pH 7.4). After washing with binding buffer, bound Histagged protein was eluted over a step-wise imidazole gradient (0.1-0.5 M) in 20 mM sodium
phosphate. Column fractions were assessed by SDS-polyacrylamide gel electrophoresis to check
for purity. L is the total cell lysate, and FT is the washed flow through fraction. Purified FarE-PD
protein band is at ~ 19 kDa (B) 0.1M fraction from A was applied onto a Resource Q ion exchange
column. Sample was eluted with a gradient buffer of 0.5M NaCl, 20mM Tris pH 8.0 (C) SDSPAGE of purified FarE-PD after fractions A1-A9 were pooled, dialyzed, concentrated, then frozen
and thawed. Arrow indicates where samples were taken for mass spectrometry analysis. (D)
Western blot for detection of FarE-PD. Gel was loaded with E. coli pQEfarE-PD lysates induced
with IPTG.
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4 Discussion
USA300 has emerged as the leading cause of S. aureus infections and a cause of life-threatening
infections irrespective of hospital or community setting due in part to its enhanced ability to persist
on human skin. In order to effectively colonize the skin, USA300 must overcome innate defence
mechanisms, including antimicrobial unsaturated free fatty acids found in the sebum and as well
as in the context of tissue abscesses where S. aureus is also exposed to high levels of linoleic acid
(101). Our lab has identified the genes farR and farE, as a regulator and effector pair that confer
resistance to unsaturated free fatty acids. farR encodes a TFR and is needed for the expression of
farE, an RND-family efflux pump that promotes efflux of uFFA. However, the exact mechanism
through which farE is regulated by farR is unclear and the aim of this research was to elucidate
the mechanism through which farE expression is regulated by FarR.

FarR belongs to the family of Type I TFR due to the divergent arrangements of genes, and on this
basis was expected to repress both its own expression, and the expression of the divergently
transcribed farE. However, FarR represents an unusual TFR as it has dual roles as both and
activator and repressor of farE expression (57, 83). FarR binds three operator sites in the farER
intergenic segment, OfarE, OfarR, and OPAL1, all of which contain a conserved TAGWTTA motif.
The positions of both OfarR and OPAL1 as overlapping the promoter of farR, would be consistent
with a role in autorepression. OfarR overlaps entirely with the farR promoter and OPAL1 lies slightly
downstream and contains PAL1, in which the TAGWTTA motif is found (Fig 1.2). We have
shown that with a loss of either this common motif in OfarR or with several nucleotide substitutions
in OPAL1, FarR is unable to bind to these operator sites (Fig 3.1B). Additionally, we have shown
evidence through EMSA of cooperative binding in which FarR firsts binds to OPAL1 and then to
OfarR, since the disruption of PAL1 also leads to loss of mobility shift attributed to binding of the
adjacent OfarR (Fig 3.1B). Cooperative binding has been shown in other TFRs as well. In Dietzia
species, regulation of alkane degradation is carried out by AlkX, which like other TFRs negatively
regulates its own expression. The inverted repeat that is bound by AlkX is unusually long, being
48 bp and AlkX has been shown to bind cooperatively as a pair of dimers to two adjacent operator
sites within (102). Additionally, QacR in S. aureus has been shown to bind cooperatively as a
dimer of dimers (75). Similarly to AlkX, QacR recognizes an unusually large inverted repeat that
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is 28 bp long. QacR functions as a tetramer and it has been shown that each dimer binds to each
inverted repeat half-site cooperatively (77).

With the loss of binding to OfarR and OPAL1, FarR is de-repressed as shown by Western blots (Fig
3.1C). FarR is more readily detected when OPAL1 is mutated, compared to the mutation of just
OfarR, further supporting our earlier finding that the binding of OfarR is dependent on initial binding
to OPAL1. Since farE cannot be expressed in the absence of FarR function, we anticipated that derepression of farR would lead to an increase in resistance to linoleic acid. However, this was not
the case, as increasing abundance of FarR seems to decrease the resistance to linoleic acid, as was
evident when the pLIfarER and pLIfarER1 or pLIfarER2 constructs were tested for their ability to
complement the USA300farER. These results are inconsistent with what was observed with the
FAR7 strain. FAR7 expresses a H121Y variant of FarR that leads to de-repression of farR
combined with constitutive expression of farE in the absence of fatty acid, and a higher induced
level of farE expression compared to wild type USA300 (56). These observations point to a
fundamental difference in the behaviour of wild type FarR and H121YFarR expressed by the FAR7
strain. Namely,

H121Y

FarR exhibited loss of binding to OfarR, leading to de-repression of farR

expression and constitutive expression of farE. In contrast, although a nucleotide substitution in
the TAGWTTA motif of OfarR was able to phenocopy the de-repression of farR observed in the
FAR7 strain, it failed to phenocopy the constitutive expression of farE and increased resistance to
linoleic acid. This can be taken as evidence to support the hypothesis that the H121Y substitution
in FarR allows the protein to mimic a ligand-bound conformation, which is necessary to activate
farE expression. Additionally, the observation that increased FarR expression does not lead to
increased resistance may be explained by the abundance of FarR in relation to the amount of ligand
present. Perhaps there needs to be an appropriate balance between FarR and its ligand in order for
proper activation of farE. Future experiments will be directed at determining the stoichiometry of
FarR and its ligand.

Importantly, the H121Y substitution of FarR7 is located in the C-terminal ligand-binding domain
of the protein, but it is the N-terminal domain that is involved in DNA recognition and binding.
Given the location of the H121Y substitution, perhaps FarR7 adopts a conformation that mimics a
ligand-bound state, leading to loss of affinity for OfarR and OPAL1, but which also promotes the

53

ability to interact with OfarE. This could explain why de-repression of farR alone is insufficient to
promote farE expression since the induction of farE expression would also be co-dependent on the
presence of an activating ligand to promote interaction with the OfarE site.

The composition of promoter spacer DNA has been shown to influence promoter activity, such
that AT-rich spacers are stronger promoters compared to those with GC-rich spacers (96, 97).
The farE promoter contains a GC-rich spacer between the -10 and -35 promoter elements,
indicating that a transcriptional activator is most likely needed. Additionally, the third operator site
of FarR, OfarE, lies upstream of the farE promoter, the position of which is consistent with a role
in activation. OfarE contains PAL2 which also contains a TAGWTTA motif. We have shown that
a G>A point mutation in the TAGWTTA motif of OfarE caused a loss in resistance to linoleic acid
(Fig 3.2A). Although we expected that this would cause a loss of affinity for OfarE, EMSA
conducted with the full intergenic segment containing this G>A substitution did not reveal any
obvious difference in the mobility shift pattern, including that the S3 shift which we had
hypothesized to be due to interaction with OfarE and the TAGWTTA motif of PAL2 (Fig 3.2B).
Conversely, EMSA done with a minimal PAL2 (OP4.1) probe revealed that FarR was unable to
bind, even though FarR was able to bind to a minimal PAL1 probe (Fig 3.3B). However, it must
be noted that all EMSA were performed in the absence of an exogenous ligand. As such, our data
are consistent with the expectation that FarR must bind a fatty acid ligand in order to recognize
the minimal PAL2 probe. FabR, a TFR in E. coli that represses genes for unsaturated fatty acid
biosynthesis functions through a similar mechanism. FabR is only able to bind the canonical FabR
binding site if it is extended by additional nucleotides. However, upon the addition of its cognate
ligand, oleoyl-CoA or palmitoyl-CoA, it is then able to bind to a minimal motif (105).

The ability of FarR to both repress and activate expression farE is unusual, and therefore, FarR
must be able to differentiate between repressing and activating operator sites. However, the three
operator sites all contain the same TAGWTTA motif. Therefore, we speculate that the three
TAGWTTA motifs within the intergenic segment of FarR all appear within a different context,
allowing FarR to differentiate between them. The TAGWTTA motif of both OPAL1 and OfarE
appears within PAL1 and PAL2, respectively, which are comprised of identical or near-identical
inverted repeat half-sites. However, they differ in the positions of IR1 and IR2a, the orientation of
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which are juxtaposed in PAL2 (Fig 3.3A). In Streptococcus pneumoniae, the TFR SczA is both an
activator and repressor of the Zn2+ efflux pump CzcD. Similar to FarR, SczA recognizes a common
TGTTCA motif in both a repressing and activating context. In the absence of Zn2+, SczA binds to
a TGTTCA motif within a perfect inverted repeat in which to repress czcD expression. In the
presence of Zn2+, SczA binds to an identical motif located within an imperfect repeat upstream
(106). Perhaps through the binding of a ligand, FarR is able to differentiate between the juxtaposed
inverted repeats of PAL1 and PAL2 in a similar fashion to SczA.

Another observation made from this study is when FarR is de-repressed and produced
constitutively, there tends to be a decrease in resistance to uFFA (Fig 3.1D). Because of these
observations, we speculate that FarR or FarE may be toxic to the cell in high amounts, explaining
why FarR is so tightly regulated through auto-repression. This is similar in the case of tetracycline
resistance. In E. coli, TetR belongs to the TFR and regulates the expression of tetA, a tetracycline
efflux pump, and studies have shown that overproduction of TetA strongly reduces fitness (107).
Another point to consider is whether FarE can discriminate between uFFA and other fatty acids
synthesized by S. aureus, such as branched-chain fatty acids (BCFA), as RND family efflux pumps
usually have a wide range of substrates (85, 86). farE and farR might be tightly regulated in order
to ensure that FarE is only activated after an accumulation of uFFA metabolites and is turned off
quickly once levels fall below the activating threshold, to prevent efflux of synthesized BCFA,
which are important in maintaining membrane fluidity and are energetically expensive to
synthesize (62).

This study has confirmed that the 5´UTR of the farR mRNA in itself is not sufficient to promote
resistance to linoleic acid (Fig 3.4B). However, these findings do not exclude the possibility of
regulation through small RNAs or riboswitches. Small RNAs (sRNA) are often utilized by both
prokaryotes and eukaryotes. In prokaryotes, they are implicated in regulating a variety of genes,
including those for plasmid maintenance through regulation of plasmid copy number or through
toxin-antitoxin systems (110). Antisense sRNAs function to control gene regulation by base
pairing to the 5´UTR of the target mRNA and inhibiting translation by blocking the RBS or
destabilizing the mRNA. There are some examples of TFRs using sRNA as a post-transcriptional
regulatory mechanism. In M. smegmatis AmtR is a global regulator of nitrogen metabolism. When
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nitrogen is abundant, cis-encoded small RNAs (sRNA) complementary to amtR mRNA block
transcription (95). Additionally, in V. harveyi, LuxR is an unusual member of the TetR family that
functions as a global regulator to repress or activate target gene expression, and LuxR expression
is regulated at the post-transcriptional level through sRNA molecules that destabilize the luxR
mRNA transcript (76, 86). Regulation by sRNA would be beneficial in situations where protein
synthesis bursts would be detrimental to fitness (110). Our observation that increased production
of FarR tends to decrease resistance to uFFA supports this notion. Additionally, the 5´ ends of farE
and farR mRNA overlap through 21nt that could negatively impact the stability or translation and
could promote degradation through RNAse III, a dsRNA dependent ribonuclease in S. aureus
(112). The 5´UTRs of the mRNA can also be involved in post-transcriptional regulation as
metabolite binding-riboswitches. Metabolite-binding riboswitches alter gene expression at the
post-transcriptional level through allosteric rearrangement in nearby mRNA structures (113). farR
or farE mRNA may be able to bind fatty acid metabolites, which can allow for subsequent
translation.
FarR contains two cysteine residues that we have shown to be important for function. Cysteine
residues have shown to be important for the function of other regulators, both through redox
reaction and through the participation in disulfide bonds. SarA in S. aureus regulates many genes
including thioredoxin reductase trxB, and along with thioredoxin trxA, is important in maintaining
a local thiol-disulfide balance within the cell. A study done by Ballal et al. found that Cys9 of
SarA is important in the regulation of trxB (97). In non-oxidizing conditions, wildtype SarA binds
to the trxB promoter to repress gene expression. It was shown through EMSA that when SarA is
incubated with oxidizing agents such as H2O2 or diamine, there is a partial disruption of the SarAtrxB promoter complex. However, when EMSA was done with mutant SarA Cys9>Gly in the
presence of oxidizing agents, there was no disruption of the SarA Cys9>Gly-promoter complex,
indicating that the oxidation of Cys9 is important for SarA function (97). Additionally, cysteine
residues have been shown to play a role in the oligomerization of TFRs. TFRs typically function
as dimers; however, there are some TFRs that bind to DNA as a dimer of dimers. CprB is a TFR
in Streptomyces coelicolor that regulates pigment production. CprB functions as a dimer of dimers,
and it has been shown that disulfide bonds between dimer pairs through Cys159 of CprB is
important for structural stability of the protein (114). Our data show that both cysteine residues of
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FarR are important for function; however, it is unknown if their importance is for the sensing of
oxidative/reductive environments, structural stability through disulfide bonds, or through another
unknown mechanism (Fig 3.5B). The strongest known inducer of farE expression is arachidonic
acid (56). Therefore, FarR being able to sense the oxidative environment of the cell may be
beneficial as arachidonic acid has been shown to kill S. aureus through a lipid peroxidation
mechanism, which creates an oxidative environment in the cell (48). C37 of FarR lies within the
N-terminal DNA binding domain, and therefore, may be in part responsible for DNA binding.
Additionally, when C37 is substituted for alanine, there is a complete lack of FarR detected in
lysates, indicating that this C37A substitution may be influencing DNA binding through superrepression of FarR (Fig 3.5C). C116 lies within the C-terminal ligand-binding domain, and we
have shown that variation of the amino acid sequence at this position can influence the relative
abundance of FarR protein as evident through Western blot analysis of cell lysate. C116YFarR was
more readily detected than C116AFarR and slightly more than wildtype FarR. However, C116YFarR
was not detected to the same extent as

H121Y

FarR (Fig 3.6). As C116 lies in close proximity to

H121, both are situated within the same -helix, and both variants of FarR appear to be derepressed compared to wild type, we speculated that a C116Y substitution may confer resistance
to linoleic acid, as does FarR7 (H121Y). Additionally, a study done by Nguyen et al. has shown
that a C116R substitution in FarR leads to constitutive expression of farE (98). Both tyrosine and
arginine are larger amino acids than histidine and cysteine, and therefore may be able to extend
into the ligand-binding pocket. This may cause FarR to adopt a ligand-bound conformation,
explaining the de-repression of farE seen in the case of FarR H121Y and FarR C116R, and the derepression of FarR we see in the case of H121Y and C116Y.

A defining characteristic of TFRs is their ability to bind a physiological ligand. However, this
study was unable to confirm the identity of this ligand. TFRs usually bind to hydrophobic ligands,
and previous studies in our lab indicate that in a USA300∆fakA background, farE expression is
constitutively elevated but cannot be induced (82). The USA300∆fakA background exhibits a
phenotype of an accumulation of non-esterified fatty acid metabolites, which may explain the
increased basal level of farE expression (85). From these observations, we hypothesize that the
ligand may be acyl-phosphates. We set out to co-express FakA, FakB2, FarR, and FarE in E. coli,
as this approach in a heterologous host, if successful, would demonstrate the minimal genes
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necessary to activate farE expression. Through Western blots, we determined that the presence of
FakA, FakB2 and phosphorylated linoleic acid did not relieve autorepression of FarR upon the
addition of linoleic acid. E. coli transformed with both pBADfakAB2 and pLIfarER was grown to
mid-exponential phase, at which point arabinose was added to induce the expression of FakA and
FakB2, and 50 M linoleic acid was added. Growth of E. coli DH5 was previously determined
not to be affected by the presence of 50 M linoleic acid, and therefore this concentration was
chosen for the duration of this experiment. E. coli is able to incorporate exogenous fatty acid into
phospholipid through acyl-CoA synthetase (FadD) (52, 92). Therefore, for future experiments, the
subinhibitory concentration of linoleic acid will be determined to ensure that there is a buildup of
acyl-phosphates within the cytosol.

We were unable to determine if the presence of FakA, FakB2, and phosphorylated linoleic acid
induced farE expression as Western blots performed with anti-FarE-PD antibodies were
unsuccessful. Anti-FarE-PD antibodies were able to detect FarE-PD but were unable to detect full
FarE protein from either E. coli transformed with farE on an inducible promoter, or in USA300
grown in the presence of linoleic acid. The lack of detectable FarE from USA300 could be
explained by the low abundance of FarE, even in inducing conditions. RND family efflux pumps
efflux a wide range of substrates that are structurally related to their main target (109). FarE may
be indiscriminately effluxing other fatty acids or membrane phospholipid derivatives, which would
be detrimental to the cell, therefore, requiring tight regulation and only be expressed when needed.
Additionally, the farE mRNA may in intrinsically unstable, again to limit the indiscriminate efflux
of phospholipid derivatives, explaining the lack of detectable FarE-PD from E. coli lysates
transformed with farE on an inducible plasmid.

Although our first line of investigation was to try to confirm acyl-phosphate as a physiological
ligand for FarR, another possibility for the activation of farE expression is that FarR requires a coactivator protein, which may include FakA or FakB1/2. In Lactococcus lactis, dihydroxyacetone
metabolism is regulated in a mechanism consisting of co-activator proteins. DhaQ binds the
physiological ligand dihydroxyacetone. The DhaQ-dihydroxyacetone complex then binds to
DhaS, a member of the TetR family. Only when DhaS binds the DhaQ-dihydroxyacetone complex
can it activate genes for dihydroxyacetone metabolism (74). DhaS is also an unconventional TFR
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in the respect that it is a transcriptional activator and not a repressor, similar to FarR. Additionally,
FarR may also be able to sense changes in membrane composition due to the incorporation of
linoleic acid similar to esxA activation. EsxA is a virulence factor in S. aureus that is secreted in
response to linoleic acid in a mechanism dependent on the incorporation of linoleic acid into
biosynthetic pathways by FakA. A decrease in the membrane fluidity due to the incorporation of
linoleic acid is suggested as a signal that activates esxA expression (117).

Overall, our data support the following mechanism of action (Fig 4.1). In the absence of a ligand,
FarR is bound to OfarR and OPAL1, repressing transcription of both farR and farE. When exogenous
unsaturated fatty acids enter the cell, they are bound by FakB2 and are then phosphorylated by
FakA. The resulting acyl-phosphate is then incorporated into membrane phospholipid by the Pls
acyltransferase system. Eventually, the buildup of acyl-phosphates exceeds the rate of
incorporation by Pls, leading to a pool of acyl-phosphates within the cytosol. At this point, FarR
binds either to the acyl-phosphates alone or to acyl-phosphates in a complex with FakA/B2,
leading to loss of affinity for OfarR/OPAL1 and binding to OfarE, activating farE expression.
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Figure 4.1 Proposed model for FarR function. (A) In the absence of ligand, FarR remains bound
to the repressing operator site, OfarR and OPAL1, inhibiting transcription of both farR and farE. (B)
When bound to its ligand, FarR is able to bind to the proposed activating operator site OfarE to
activate farE expression. Proposed ligands of FarR include (C) acyl-phosphates or (D) acylphosphates as a complex with FakA/B2.
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This study was unable to determine the ligand of FarR and future research will be directed at
elucidating the identity of this ligand. We hypothesize that the ligand may be acyl-phosphates on
its own, or perhaps FakA/FakB2 acyl-phosphate complex. To determine if this is the case, FakA
and FakB2 will be purified and an in vitro phosphorylation assay will be done to produce acylphosphates. The resulting cocktail will then be added to EMSA buffer to determine if the presence
of FakA, FakB2, or phosphorylated linoleic acid modulated the DNA binding affinity of FarR for
operator sites. For this purpose, we would use the minimal PAL2 probe, as this represents the site
that is predicted to function in the activation of farE expression, and FarR fails to bind to minimal
PAL2 in the absence of ligand. Additionally, if FarR behaves in a similar manner to DhaS, it may
be binding to FakA/FakB2 in complex with an acyl-phosphate. To determine whether it is the acylphosphates alone, or a FakA/FakB2/acyl-phosphate complex, the acyl-phosphates will be
separated via chloroform extraction prior to being used in EMSA. Future research will also be
targeted at further understanding the role that cysteines play in FarR function. As we have
determined that both Cys37 and Cys116 are important for the growth of USA300 at 50 M linoleic
acid. EMSA will be done with C37AFarR and C116AFarR to determine whether the cysteine residues
are necessary for DNA binding.

In summary, we have studied the regulation of uFFA efflux pump FarE by TetR family
transcriptional regulator FarR. Results of this study have provided evidence that FarR recognizes
a conserved TAGWTTA that appears three times within the intergenic segment. We have shown
that FarR is able to auto-repress its own expression through the cooperative binding of OPAL1 and
OfarR; however, this de-repression of farR does not increase resistance to linoleic acid. This study
has also identified the importance of cysteine residues in FarR function. The ligand of FarR is still
yet to be determined. Cumulatively, these findings further elucidate the regulation of farE, and
give us a better understanding of the mechanisms utilized by S. aureus to persist on and to colonize
the human skin.
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